EP1080225A1 - Compositions and methods for the pulmonary delivery of nucleic acids - Google Patents

Abstract

The present invention relates to compositions and methods for the pulmonary delivery of nucleic acids, particularly oligonucleotides. In one preferred embodiment, the compositions and methods of the invention are utilized to effect the pulmonary delivery of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic or prophylactic purposes.

Description

COMPOSITIONS AND METHODS FOR THE PULMONARY DELIVERY OF NUCLEIC ACIDS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application serial no. 09/083,586 filed on May 21, 1998, the disclosure of which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

The present invention relates to compositions and methods for the delivery of nucleic acid therapeutics and diagnostics to the lung of an animal, particularly a human. More particularly, the present invention is directed to compositions and methods for the pulmonary delivery of oligonucleotide therapeutics and diagnostics, including antisense oligonucleotides. In some preferred embodiments, the present invention is directed to methods and compositions for pulmonary delivery of oligonucleotide therapeutic compositions comprising penetration enhancers, carrier compounds and/or transfection agents. More specific objectives and advantages of the invention will hereinafter be made clear or become apparent to those skilled in the art during the course of explanation of preferred embodiments of the invention.

BACKGROUND OF THE INVENTION Advances in the field of biotechnology have given rise to significant advances in the treatment of previously- intractable diseases such as cancer, genetic diseases, arthritis and AIDS. Many such advances involve the administration of oligonucleotides and other nucleic acids to a subject, particularly a human subject.

Oligonucleotides have been administered by various routes. For example, oligonucleotides administered by parenteral routes have been shown to be effective for the treatment of diseases and/or disorders. See, e . g. , U.S. Patent No. 5,595,978, January 21, 1997 to Draper et al . , which discloses intravitreal injection as a means for the direct delivery of antisense oligonucleotides to the vitreous humor of the mammalian eye. See also, Robertson, Nature Biotechnology, 1997, 15:209 and Anon., Genetic Engineering News , 1991 , 15 : 1 , each of which discuss the treatment of Crohn's disease via intravenous infusions of antisense oligonucleotides.

The administration of oligonucleotides via the lung for the treatment of pulmonary disorders is attractive because oligonucleotide is delivered directly to the target organ. For reviews see, for example, Nyce, J.W., Exp .

Opin . Invest . Drugs (1997) 6 (9) : 1149-1156; Schreier, H.,

Advanced Drug Delivery Reviews, 19, (1996) 1-2; u-Pong,

S., and Byron, P.R., Advanced Drug Delivery Revi ews , 19, (1996) 47-71; and Phan, S.H., Thorax 1995; 50: 415-421.

However, most reports have focused upon intratracheal rather than inhalation delivery of large nucleic acids that are antisense constructs rather than of antisense oligonucleotides having smaller molecular weights. See, for example, Georges, R.N., et al . , Cancer Research 53,

1743-1746 (1993) (prevention of orthotopic human lung cancer growth by intratracheal installation of a retroviral antisense K-ras construct); and Yoshimura, K., et al . ,

Nucleic Acids Research, Vol. 20, No. 12, 3233-3240 (1992) (expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung after in vivo intratracheal plasmid-mediated gene transfer) .

Antisense oligonucleotides have been shown to demonstrate antisense effect upon cells of various diseases or disorders, including cancer. See, for example, Dosaka- Akita et al . , Cancer Res. 55, 1559-1564 (1995) (inhibition of proliferation by L-myc antisense DNA for the transitional initiation site in human small cell lung cancer) .

There is a long-felt need for compositions which can effectively provide for the pulmonary delivery of nucleic acids, particularly oligonucleotides, more particularly oligonucleotides having one or more chemical modifications, together with methods for using such compositions to deliver such oligonucleotides and nucleic acids into the lung of an animal. The present invention is directed to these, as well as other, important ends.

SUMMARY OF THE INVENTION

The present invention is directed to compositions and methods for pulmonary delivery of oligonucleotides. In some preferred embodiments, the present invention provides pharmaceutical compositions for pulmonary delivery of an oligonucleotide comprising at least one oligonucleotide wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' - deoxyribofuranosyl sugar moiety or at least one internucleotide linkage within said oligonucleotide is not a phosphodiester or a phosphorothioate linkage.

Also provided in accordance with the present invention are methods for the administration of an nucleic acid therapeutic or diagnostic composition comprising: preparing a nucleic acid therapeutic or diagnostic composition; aerosolizing the nucleic acid composition; introducing the aerosolized nucleic acid composition into the lung of a mammal; and wherein the aerosolized nucleic acid composition comprises at least one oligonucleotide wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' -deoxyribofuranosyl sugar moiety or at least one internucleotide linkage within said oligonucleotide is not a phosphodiester or a phosphorothioate linkage.

The present invention also provides methods of treating an animal having or suspected of having a disease or disorder that is treatable with one or more nucleic acids comprising administering a therapeutically effective amount of an aerosolized nucleic acid composition to the lung of the animal, wherein the aerosolized nucleic acid composition comprises at least one oligonucleotide wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' -deoxyribofuranosyl sugar moiety or at least one internucleotide linkage within said oligonucleotide is not a phosphodiester or a phosphorothioate linkage.

Also provided by the present invention are methods of investigating the role of gene or gene product in an animal other than a human comprising administering a therapeutically effective amount of an aerosolized nucleic acid composition to the lung of the animal, wherein the aerosolized nucleic acid composition comprises at least one oligonucleotide wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' - deoxyribofuranosyl sugar moiety or at least one internucleotide linkage within said oligonucleotide is not a phosphodiester or a phosphorothioate linkage . In some preferred embodiments, methods are provided for delivering an oligonucleotide therapeutic or diagnostic compound to the lung of an animal comprising applying to said lung a pharmaceutical composition according to the invention. Preferably, the oligonucleotide is delivered within cells of said lung. In some preferred embodiments, the methods of the invention are performed on an animal that is known or suspected to suffer from a disease or disorder. In some preferred embodiments, the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' -deoxyribofuranosyl sugar moiety.

In further preferred embodiments, said nucleoside unit is a 2 ' -O-substituted nucleoside unit.

In some particularly preferred embodiments, said 2-0- substituent of said 2 ' -O-substituted nucleoside unit is a 2 ' -O-alkoxyalkoxy substituent.

In some particularly preferred embodiments, said 2-0- substituent of said 2 ' -O-substituted nucleoside unit is a 2 ' -O-dialkylaminooxyalkyl substituent .

In some preferred embodiments, at least one internucleotide linkage within said oligonucleotide is not a phosphodiester or a phosphorothioate linkage. In further preferred embodiments, at least one internucleotide linkage within said oligonucleotide is a 3 ' -methylenephosphonate, a non-phosphorus containing oligonucleoside linkage, a 2 '-5' linkage or is a 3 ' -deoxy- 3 ' -amino phosphora ide linkage. In some preferred embodiments, the compositions further comprise one or more pharmaceutically acceptable carriers .

In some preferred embodiments, said composition is in aqueous media. In other preferred embodiments, said aqueous media is sterilized, pyrogen free water. In further preferred embodiments, said aqueous media is saline solution. In still further preferred embodiments, the pharmaceutical composition is a powder.

Preferably, the compositions of the invention comprise an oligonucleotide that is an antisense oligonucleotide.

In some preferred embodiments, said antisense compound modulates the expression of a protein or modulates a rate of cellular proliferation. In further preferred embodiments, said antisense oligonucleotide modulates expression of a cellular adhesion protein.

In still further preferred embodiments, the antisense oligonucleotide is antisense to a genetic sequence implicated in a disease or disorder, preferably, asthma, a cancer of the lung, pulmonary fibrosis, rhinovirus, tuberculosis, bronchitis, or pneumonia.

In some preferred embodiments, said antisense oligonucleotide is antisense to a portion of a gene coding for a cytokine . In further preferred embodiments, said antisense oligonucleotide is antisense to a portion of a gene coding for ICAM-1, ELAM-1, VCAM-1, B7-1, B7-2, CD40, LFA-3, PECAM-1, a ras oncogene, an H-ras oncogene, a K-ras oncogene, Protein Kinase C, or to a unique portion of the genome of ycoJbacterium tuberculosis, M. bovis , or

Streptococcus pneumoniae .

In some preferred embodiments, the pharmaceutical compositions of the invention comprise more than one antisense oligonucleotide. In further preferred embodiments, the oligonucleotide is a ribozyme, an external guide sequence, or an antisense peptide nucleic acid.

In further preferred embodiments, said oligonucleotide is an aptamer or a molecular decoy. In further preferreed embodiments, said aqueous media is sterilized, pyrogen free buffer solution.

In some preferred embodiments, the nucleic acid therapeutic composition is an aerosolized solution that consists essentially of an antisense oligonucleotide in saline solution.

In other preferred embodiments, the nucleic acid therapeutic composition is an aerosolized solution that consists essentially of an antisense oligonucleotide in buffer solution. The present invention also provides methods of modulating the expression of a gene in an animal comprising administering to said animal the pharmaceutical composition of the invention.

The present invention also provides medical devices for pulmonary delivery of an aerosol comprising a pharmaceutical composition in accordance with the present invention. Preferably, the medical device is a nebulizer. In a further aspect, the present invention provides novel compounds comprising at least one moiety of Formula:

wherein:

R₂ has the formula -0-R₅-0-R₆;

R₅ and R₆ are independently alkyl having from 1 to about five carbons; and

Q is 5-methylcytosine .

In especially preferred embodiments, R₅ is -CH₂-CH₂- and R₆ is -CH_:..

In further preferred embodiments, compounds are provided having the formula :

wherein:

R_α has the formula -0-R₅-0-R₆;

R; and R₆ are independently alkyl having from 1 to about five carbons;

Q is 5-methylcytosine;

M is an internucleoside linkage;

B is a nucleobase; each R_: is H, OH, F, or a group of formula R₇-(R₈)_V; R- is C₃-C₂₀ alkyl, C₄-C₂₀ alkenyl, C₂-C₂₀ alkynyl , C₁-C₂₀ alkoxy, C₂-C₂₀ alkenyloxy, or C_-C₂₀ alkynyloxy;

R₈ is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, 0-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O- aryl, S-aryl, NH-aryl, 0-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, inter- calator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmaco- kinetic properties of oligonucleotides;

R₃ is H or a hydroxyl protecting group; R₄ is H, OH, an internucleoside linkage, a linker connected to a solid support, or a group of formula -O-Pr where Pr is a hydroxyl protecting group; and m and n are each independently from 0 to about 50.

In some preferred embodiments, R₅ is -CH₂-CH₂- and R₆ is -CH₃. In further preferred embodiments, each R₂ is -0-CH₂- CH₂-0-CH₃.

In some especially preferred embodiments, each R₂ is -0-CH₂-CH₂-0-CK,, and B is selected from the group consisting of 5-methylcytosine, adenine, guanine, uracil and thymine .

In particularly preferred embodiments, oligonucleotides are provided comprising one or more 5- methylcytosine-2 ' -methoxyethoxy nucleosidic moieties.

In further particularly preferred embodiments, pharmaceutical compositions are provided comprising a compound of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The numerous objects and advantages of the present invention may be better understood by those skilled in the art by reference to the accompanying figures, in which:

Figure 1 is a plot showing that oligonucleotides were uniformly nebulized, and that the size of the resultant particles is not altered over time.

Figure 2 shows nebulization of oligonucleotide (ISIS 2503; 40 mg/ml by a PulmoAide Nebulizer (Apguard Medical, Inc., Woodland Hills, CA) for a period of 20 minutes. The mist coming out of the nebulizer was collected in an impinger and was analyzed for oligonucleotide content by ultraviolet absorption. The straight line of the graph indicates that the nebulization was uniform over the course of the experiment. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention provides compositions and methods for the pulmonary delivery of oligonucleotides and other nucleic acids to the lung of an animal. In preferred embodiments, the present invention provides compositions and methods for modulating the in vivo expression of a gene in an animal through the pulmonary administration of an antisense oligonucleotide, thereby bypassing the complications and expense which may be associated with intravenous and other routes of administration. Enhanced delivery of the oligonucleotides and other nucleic acids to the lung of an animal is achieved through the use of the compositions and methods of the invention.

Studies suggest that oligonucleotides are rapidly eliminated from plasma and accumulate mainly in the liver and kidney after i.v. administration (Miyao et al . ,

Antisense Res . Dev. , 1995, 5:115; Takakura et al . ,

Antisense & Nucl . Acid Drug Dev. , 1996, 6 : 111 ) . Means for measuring and avoiding "first pass clearance" effects are needed for the development of effective agents to treat diseases or disorders of the lung.

One means of ameliorating first pass clearance effects is to increase the dose of an administered drug, thereby compensating for proportion of drug lost to first pass clearance. Although this may be readily achieved with i.v. administration by, for example, simply providing more of the drug to an animal, other factors influence the bioavailability of administred drugs.

The present invention provides compositions for the pulmonary administration of oligonucleotides that can contain carrier compounds, penetration enhancing agents, and transfection agents. However, the present invention also provides compositions and methods for the pulmonary administration of oligonucleotides that are substantially free of As used herein, the term "substantially free of carriers or penetration enhancing agents" means that a de minimis amoun: (i.e., an amount less than that recognized to be effective) of carriers or penetration enhancing agents can be present in the composition. In particular, these modalities of the invention are drawn to compositions that comprise less than 10 mole percent, preferably less than 1 mole percent and most preferably less than 0.1 mole percent of such carriers or penetration enhancing agents . In some preferred embodiments, the present invention provides pharmaceutical compositions for pulmonary administration of large molecule therapeutics such as oligonucleotides comprising the oligonucleotide and at least one substance which facilitates the transport of a drug across the mucous membrane (s) of the lung (so called "mucosal penetration enhancers, " also known as "absorption enhancers" or simply as "penetration enhancers"). See Muranishi, Crit. Rev. Ther. Drug Carrier Systems, 1990, 7:1 and Lee et al . , Cri t . Rev. Ther. Drug Carrier Systems ,

1991, 8:91.

The present invention provides compositions and methods for pulmonary delivery of one or more nucleic acids to an animal. For purposes of the invention, the term "animal" is meant to encompass humans as well as other mammals, as well as reptiles, fish, amphibians, and birds. The term "pulmonary delivery" refers to the administration, directly or otherwise, to a portion of the lung of an animal. The term "lung" has its accustomed meaning as the chief organ of respiration (i.e. gas exchange) in an animal. As used herein, the term "pulmonary delivery" subsumes the absorption of the delivered component from the interior surface of lung, into the lung tissue. The present invention provides compositions and methods for the pulmonary administration of oligonucleotides. The compositions can contain carrier compounds, penetration enhancing agents, and/or transfection agents. As used herein, "carrier compound" refers to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioated oligonucleotide in hepatic tissue is reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4- acetamido-4 ' isothiocyano-stilbene-2 , 2 ' -disulfonic acid (Miyao et al . , Antisense Res . Dev. , 1995, 5:115; Takakura et al . , Antisense & Nucl . Acid Drug Dev. , 1996, 6 : 111 ) .

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal . The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers { e . g. , lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants { e . g. , magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic εtearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrates (e.g., starch, sodium starch glycolate, etc.); or wetting agents (e.g., sodium lauryl sulphate , etc. ) .

In some preferred embodiments, the present invention employs oligonucleotides for use in antisense modulation of the function of DNA or messenger RNA (mRNA) encoding a protein the modulation of which is desired, and ultimately to regulate the amount of such a protein. Hybridization of an antisense oligonucleotide with its mRNA target interferes with the normal role of mRNA and causes a modulation of its function in cells. The functions of mRNA to be interfered with include all vital functions such as translocation of the RNA to the site for protein translation, actual translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, turnover or degradation of the mRNA and possibly even independent catalytic activity which may be engaged in by the RNA. The overall effect of such interference with mRNA function is modulation of the expression of a protein, wherein "modulation" means either an increase (stimulation) or a decrease ;inhibition) in the expression of the protein. In the context of the present invention, inhibition is the preferred form of modulation of gene expression.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as oligonucleotides having non-naturally- occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target and increased stability in the presence of nucleases . An oligonucleotide is a polymer of repeating units generically known as a nucleotides. An unmodified (naturally occurring) nucleotide has three components: (1) a nitrogenous base linked by one of its nitrogen atoms to (2) a 5-carbon cyclic sugar and (3) a phosphate, esterified to carbon 5 of the sugar. When incorporated into an oligonucleotide chain, the phosphate of a first nucleotide is also esterified to carbon 3 of the sugar of a second, adjacent nucleotide. The "backbone" of an unmodified oligonucleotide consists of (2) and (3) , that is, sugars linked together by phosphodiester linkages between the carbon 5 (5') position of the sugar of a first nucleotide and the carbon 3 (3') position of a second, adjacent nucleotide. A "nucleoside" is the combination of (1) a nucleobase and (2) a sugar in the absence of (3) a phosphate moiety (Kornberg, A., DNA Replication, W.H.

Freeman & Co., San Francisco, 1980, pages 4-7) . The backbone of an oligonucleotide positions a series of bases in a specific order; the written representation of this series of bases, which is conventionally written in 5 ' to 3' order, is known as a nucleotide sequence.

Oligonucleotides may comprise nucleotide sequences sufficient in identity and number to effect specific hybridization with a particular nucleic acid. Such oligonucleotides which specifically hybridize to a portion of the sense strand of a gene are commonly described as "antisense." In the context of the invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleotides. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary, " as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that an oligonucleotide need not be 100% complementary to its target DNA sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a decrease or loss of function, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, or in the case of in vi tro assays, under conditions in which the assays are performed. Antisense oligonucleotides are commonly used as research reagents, diagnostic aids, and therapeutic agents.

For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes, for example to distinguish between the functions of various members of a biological pathway. This specific inhibitory effect has, therefore, been harnessed by those skilled in the art for research uses. The specificity and sensitivity of oligonucleotides is also harnessed by those of skill in the art for therapeutic uses. For example, the following U.S. patents demonstrate palliative, therapeutic and other methods utilizing antisense oligonucleotides. U. S. Patent No. 5,135,917 provides antisense oligonucleotides that inhibit human interleukin-1 receptor expression. U.S. Patent No. 5,098,890 is directed to antisense oligonucleotides complementary to the c-myb oncogene and antisense oligonucleotide therapies for certain cancerous conditions . U.S. Patent No. 5,087,617 provides methods for treating cancer patients with antisense oligonucleotides. U.S. Patent No. 5,166,195 provides oligonucleotide inhibitors of Human Immunodeficiency Virus (HIV) . U.S. Patent No. 5,004,810 provides oligomers capable of hybridizing to herpes simplex virus Vmw65 mRNA and inhibiting replication. U.S. Patent No. 5,194,428 provides antisense oligonucleotides having antiviral activity against influenzaviruε . U.S. Patent No. 4,806,463 provides antisense oligonucleotides and methods using them to inhibit HTLV-III replication. U.S. Patent No. 5,286,717 provides oligonucleotides having a complementary base sequence to a portion of an oncogene. U.S. Patent No. 5,276,019 and U.S. Patent No. 5,264,423 are directed to phosphorothioate oligonucleotide analogs used to prevent replication of foreign nucleic acids in cells. U.S. Patent No. 4,689,320 is directed to antisense oligonucleotides as antiviral agents specific to cytomegalovirus (CMV) . U.S. Patent No. 5,098,890 provides oligonucleotides complementary to at least a portion of the mRNA transcript of the human c-myb gene. U.S. Patent No. 5,242,906 provides antisense oligonucleotides useful in the treatment of latent Epstein-Barr virus (EBV) infections. Other examples of antisense oligonucleotides are provided herein. The oligonucleotides in accordance with this invention preferably comprise from about 8 to about 30 nucleotides. It is more preferred that such oligonucleotides comprise from about 15 to 25 nucleotides. As is known in the art, a nucleotide is a base-sugar combination suitably bound to an adjacent nucleotide through a phosphodiester, phosphorothioate or other covalent linkage . In the context of this invention, the term "oligonucleotide" includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as oligonucleotides having non-naturally- occurring portions which function similarly. Such modified or substituted oligonucleotides may be preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target and increased stability in the presence of nucleases .

Oligonucleotides are also useful in determining the nature, function and potential relationship to body or disease states in animals of various genetic components of the body. Heretofore, the function of a gene has been chiefly examined by the construction of loss-of-function mutations in the gene (i.e., "knock-out" mutations) in an animal (e.g., a transgenic mouse). Such tasks are difficult, tine-consuming and cannot be accomplished for genes essential to animal development since the "knock-out" mutation would produce a lethal phenotype. Moreover, the loss-of-function phenotype cannot be transiently introduced during a particular part of the animal's life cycle or disease state; the "knock-out" mutation is always present. "Antisense knockouts," that is, the selective modulation of expression of a gene by antisense oligonucleotides, rather than by direct genetic manipulation, overcomes these limitations (see, for example, Albert et al . , Trends in

Pharmacological Sciences , 1994, 15:250) . In addition, some genes produce a variety of mRNA transcripts as a result of processes such as alternative splicing; a "knock-out" mutation typically removes all forms of mRNA transcripts produced from such genes and thus cannot be used to examine the biological role of a particular mRNA transcript. By providing compositions and methods for the simple alimentary delivery of oligonucleotides and other nucleic acids, the present invention overcomes these and other shortcomings.

The present invention further encompasses compositions employing ribczymes . Synthetic RNA molecules and derivatives thereof that catalyze highly specific endoribonuclease activities are known as ribozymes . (See, generally, U.S. Patent No. 5,543,508 to Haseloff et al . , issued August 5, 1996, and U.S. Patent No. 5,545,729 to Goodchild et al . , issued August 13, 1996.) The cleavage reactions are catalyzed by the RNA molecules themselves . In naturally occurring RNA molecules, the sites of self- catalyzed cleavage are located within highly conserved regions of RNA secondary structure (Buzayan et al . , Proc . Na tl . Acad . Sci . U. S . A . , 1986, 83 , 8859; Forster et al . ,

Cell , 1987 , 50, 9) . Naturally occurring autocatalytic RNA molecules have been modified to generate ribozymes which can be targeted to a particular cellular or pathogenic RNA molecule with a high degree of specificity. Thus, ribozymes serve the same general purpose as antisense oligonucleotides (i.e., modulation of expression of a specific gene and, like oligonucleotides, are nucleic acids possessing significant portions of single- strandednesε . That is, ribozymes have substantial chemical and functional identity with oligonucleotides and are thus considered to be equivalents for purposes of the present invention.

Other biologically active oligonucleotides may be formulated in the compositions of the invention and used for therapeutic, palliative or prophylactic purposes according to the methods of the invention. Such other biologically active oligonucleotides include, but are not limited to, antisense compounds including, inter alia, antisense oligonucleotides, antisense PNAs and ribozymes (described supra) and EGSs, as well as aptamers and molecular decoys (described infra) .

Sequences that recruit RNase P are known as External Guide Sequences, hence the abbreviation "EGS." EGSs are antisense compounds that direct of an endogenous nuclease (RNase P) to a targeted nucleic acid (Forster et al . ,

Science, 199C, 249 , 783; Guerrier-Takada et al . , Proc .

Na tl . Acad . Sci . USA, 1997, 94 , 8468) .

Antisense compounds may alternatively or additionally comprise a synthetic moiety having nuclease activity covalently linked to an oligonucleotide having an antisense sequence instead of relying upon recruitment of an endogenous nuclease. Synthetic moieties having nuclease activity include, but are not limited to, enzymatic RNAs (as in ribozymes) , lanthanide ion comlexes, and the like (Haseloff et al . , Nature, 1988, 334 , 585; Baker et al . , J. Am . Chem . Soc . , 1997, 119 , 8749) .

Aptamers are single-stranded oligonucleotides that bind specific ligands via a mechanism other than Watson- Crick base pairing. Aptamers are typically targeted to, e.g., a protein and are not designed to bind to a nucleic acid (Ellington et al . , Nature, 1990, 346, 818).

Molecular decoys are short double-stranded nucleic acids (including single-stranded nucleic acids designed to "fold back" on themselves) that mimic a site on a nucleic acid to which a factor, such as a protein, binds. Such decoys are expected to competitively inhibit the factor; that is, because the factor molecules are bound to an excess of the decoy, the concentration of factor bound to the cellular site corresponding to the decoy decreases, with resulting therapeutic, palliative or prophylactic effects. Methods of identifying and constructing nucleic acid decoy molecules are described in, e.g., U.S. Patent

5,716,780 to Edwards et al .

Another type of bioactive oligonucleotide is an RNA- DNA hybrid molecule that can direct gene conversion of an endogenous nucleic acid (Cole-Strauss et al . , Science,

1996, 273 , 1386) .

It has been discovered in accordance with the present invention that pulmonary administration of phosphodiester oligonucleotides is particularly advantageous. Specifically, it has been discovered in accordance with the present invention that the level of nuclease activity in lung tissue is sufficiently low to afford phosphodiester oligonucleotides longer lifetimes in lung tissue than was previously believed. Accordingly, contrary to conventional knowledge in the art (see, e.g., Wu-Pong et al . , Adv. Drug

Delivery, 1996 , 19 , 47), phosphodiester antisense oligonucleotides reside undegraded in the lung for a sufficiently long period of time to exert an antisense effect.

In further preferred embodiments, the present invention provides oligonucleotides, preferably phosphodiester and phosphorothioate oligonucleotides, that have at least one 2 ' -alkoxy-alkyloxy substituent, which is preferably, 2 ' -methoxyethoxy . It has been discovered that the presence of such 2 ' -alkoxy-alkyloxy substituents confer nuclease resistance, and increased binding. A further preferred modification includes 2 ' -dimethylaminooxyethoxy, i.e., a 0(CH_:) _;ON(CH₃)₂ group, also known as 2'-DMA0E, as described in co-owned United States patent application Serial Number 09/016,520, filed on January 30, 1998, the contents of which are herein incorporated by reference.

Other preferred modifications include 2 ' -methoxy (2'-0-CH₃), 2 ' -aminopropoxy (2 ' -OCH₂CH₂CH₂NH₂) and 2'-fl oro (2 ' -F) .

Other specific oligonucleotide chemical modifications are described in the following subsections. It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the following modifications may be incorporated in a single antisense compound or even in a single residue thereof, for example, at a single nucleoside within an oligonucleotide. Base Modifications: For each nucleoside of an oligonucleotide, the base portion of the nucleoside may be selected from a large palette of different base units available. These may be 'modified' or 'natural' bases (also reference herein as nucleobases) including the natural purine bases adenine (A) and guanine (G) , and the natural pyrimidine bases thymine (T) , cytosine (C) and uracil (U) . They further can include modified nucleobases including other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C) , 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2- thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5- uracil (pseudouracil) , 4-thiouracil, 8 -halo, 8-amino, 8- thiol, 8-thioalkyl, 8-hydroxyl and other 8 -substituted adenines and guanines, 5-halo uracils and cytosines particularly 5-bromo, 5-trifluoromethyl and other 5- substituted uracils and cytosines, 7-methylguanine and 7- methyladenine, 8-azaguanine and 8-azaadenine, 7- deazaguanine and 7-deazaadenine and 3-deazaguanine and 3- deazaadenine . Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in the Concise Encyclopedia Of Polymer Science And

Engineering, pages 858-859, Kroschwitz, J.I., ed. John

Wiley & Sons, 1990, those disclosed by Englisch et al . ,

Angewandte Che ie, International Edi tion, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, Antisense

Research and Applications , pages 289-302, Crooke, S.T. and

Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6- azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2 -air.inopropyladenine, 5-propynyluracil and 5- propynylcytoεine . 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds . ,

Antisense JResearch and Applications , CRC Press, Boca Raton,

1993, pp. 276-278) and are presently preferred for selection as the base. These are particularly useful when combined with a 2 ' -methoxyethyl εugar modifications, described below.

Further representative nucleobases include adenine, guanine, cytosine, uridine, and thymine, as well as other non-naturally occurring and natural nucleobases such as xanthine, hypcxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halo uracil and cytosine, 6-azo uracil, cytosine and thymine, 5- uracil (pseudo uracil) , 4-thiouracil, 8 -halo, oxa, amino, thiol, thioalkyl, hydroxyl and other 8-εubεtituted adenines and guanines, 5-trifluoromethyl and other 5-εubεtituted uracilε and cytoεineε, 7-methylguanine . Further naturally and non naturally occurring nucleobaεeε include those disclosed in U.S. Patent No. 3,687,808 (Merigan, et al . ) , in chapter 15 by Sanghvi, in Antisense Research and

Application, Ed. S. T. Crooke and B. Lebleu, CRC Press,

1993, in Englisch et al . , Angewandte Chemie, International Edition, 1991, 30, 613-722 (see especially pages 622 and

623, and in the Concise Encyclopedia of Polymer Science and

Engineering, J.I. Kroschwitz Ed., John Wiley & Sons, 1990, pages 858-859, Cook, P.D., Anti -Cancer Drug Design, 1991,

6, 585-607, each of which are hereby incorporated by reference in their entirety. The term 'nucleosidic base' is further intended to include heterocyclic compounds that can serve as like nucleosidic bases including certain 'universal bases' that are not nucleosidic bases in the most claεεical sense but serve as nucleosidic bases. Especially mentioned aε a univerεal base is 3-nitropyrrole . Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Patent 3,687,808, as well aε U.S. Patentε 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5 , 681 , 41 , Reference iε alεo made to allowed United Stateε patent application 08/762,488, filed on December 10, 1996, commonly owned with the preεent application and herein incorporated by reference.

In εelecting the base for any particular nucleoside of an oligonucleotide, consideration is first given to the need of a baεe for a particular εpecificity for hybridization to an oppoεing strand of a particular target. Thus if an 'A' base is required, adenine might be selected however other alternative baseε that can effect hybridization in a manner mimicking an 'A' baεe such as 2 , 6-diaminopurine might be selected should other considerεation, e.g., εtronger hybridization (relative to hybridization achieved with adenine) , be desired.

Sugar Modifications: For each nucleoside of an oligonucleotide, the sugar portion of the nucleoεide may be εelected from a large palette of different εugar or εugar surrogate unitε available. Theεe may be modified sugar groups, for instance sugarε containing one or more εubεtituent groupε . Preferred εubεtituent groupε compriεe the following at the 2' poεition: OH; F; 0- , S-, or N- alkyl, 0-, S-, or N-alkenyl, or 0, S- or N-alkynyl, wherein the alkyl, alkenyl and alkynyl may be εubstituted or unsubεtituted C_x to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are 0 [ (CH₂) _n0]_mCH₃, 0(CH₂)_nOCH₃, 0(CH₂)_nNH_2, 0(CH₂)_nCH_3, 0(CH₂)_nONH₂, and 0(CH₂)_n0N[ (CH₂)„CH₃) ]_2/ where n and m are from 1 to about 10. Other preferred substituent groups comprise one of the following at the 2' poεition: C_α to C₁₀ lower alkyl, subεtituted lower alkyl, alkaryl, aralkyl, 0-alkaryl or 0- aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF_3, 0CF₃, SOCH₃ S0₂CH₃, 0N0_2/ N0₂ N_3; NH₂ heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic propertieε of an oligonucleotide, or a group for improving the pharmacodynamic propertieε of an oligonucleotide, and other εubstituents having εimilar propertieε. A preferred modification includeε 2 ' -methoxyethoxy (2 ' -0-CH₂CH₂OCH₃, alεo known aε 2 ' -0- (2-methoxyethyl) or 2 ' -MOE) (Martin et al., Helv. Chim . Acta, 1995, 78, 486) i.e., an alkoxyalkoxy group. A further preferred modification includeε 2'- dimethylamino oxyethoxy, i.e., a 0 (CH₂) ₂ON(CH₃) , group, alεo known aε 2'-DMA0E, aε deεcribed in co-owned United Stateε patent application Serial Number 09/016,520, filed on January 30, 1998, the contentε of which are herein incorporated by reference.

Other preferred modifications include 2 ' -methoxy (2 ' - 0-CH₃) , 2 ' -aminopropoxy (2 ' -OCH₂CH₂CH₂NH₂) and 2 ' -fluoro (2 ^■ - F) . Similar modifications may also be made at other positionε on the sugar group, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2 '-5' linked oligonucleotides and the 5 ' position of 5 ' terminal nucleotide. The nucleosides of the oligonucleotideε may alεo have sugar mimetics such as cyclobutyl moieties in place of the pentofuranoεyl εugar.

Representative United States patents that teach the preparation of εuch modified εugarε structureε include, but are not limited to, U.S. Patentε 4,981,957; 5,118,800, 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786, 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722 5,597,909; 5,610,300; 5,627,053 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the preεent application, each of which iε herein incorporated by reference, together with allowed United Stateε patent application 08/468,037, filed on June 5, 1995, which iε commonly owned with the preεent application and iε herein incorporated by reference. Modified Linkageε (Backboneε) : In addition to phoεphodieεter linkages, specific examples of some preferred modified oligonucleotides envisioned for this invention include thoεe containing modified internucleoεidic linkages, depicted as moiety "M" in the compounds described herein. These internucleoside linkages are also referred to as linkers, backbones or oligonucleotide backbones. For forming these nucleoside linkages, a palette of different internucleoside linkages or backbones is available. These include modified oligonucleotide backbones, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phoεphotri- eεterε, aminoalkylphoεphotrieεterε, methyl and other alkyl phoεphonates including 3 ' -alkylene phosphonateε and chiral phoεphonateε, phoεphinates, phosphoramidates including 3'- amino phoεphoramidate and aminoalkylphoεphoramidates, thionophosphoramidates , thionoalkylphosphonates , thionoalklyphosphotrieεterε, and boranophosphates having normal 3 '-5' linkages, 2 '-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoεide unitε are linked 3 '-5' to 5 '-3' or 2 '-5' to 5 '-2'. Various saltε, mixed εaltε and free acid formε are alεo included.

Representative United States patents that teach the preparation of the above phosphorus containing linkages include, but are not limited to, U.S. Patents 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897, 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131, 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677, 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111, 5,563,253; 5,571,799; 5,587,361; 5,625,050; and 5 , 697 , 248 , certain of which are commonly owned with this application, and each of which iε herein incorporated by reference.

Preferred internucleoεide linkageε for oligonucleotideε that do not include a phosphorus atom therein, i.e., for oligonucleosideε, have backbones that are formed by short chain alkyl or cycloalkyl intersugar linkageε, mixed heteroatom and alkyl or cycloalkyl intersugar linkages, or one or more short chain heteroatomic or heterocyclic intersugar linkages . These include those having morpholino linkageε (formed in part from the εugar portion of a nucleoεide) ; εiloxane backboneε; εulfide, εulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backboneε; εulfamate backboneε; methyleneimino and methylenehydrazino backboneε; εulfonate and εulfonamide backboneε; amide backboneε; and otherε having mixed N, 0, S and CH component partε.

Repreεentative United Stateε Patentε that teach the preparation cf the above oligonucleosideε include, but are not limited to, U.S. Patentε 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5 , 677 , 439 , certain of which are commonly owned with this application, and each of which is herein incorporated by reference. In other preferred oligonucleotideε, i.e., oligonucleotide mimeticε, both the εugar and the interεugar linkage, i.e., the backbone, of the nucleotide unitε are replaced with novel groups . The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been εhown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA) . In PNA compounds, the sugar-phosphate backbone of an oligonucleotide is replaced with an amide-containing backbone, in particular an aminoethylglycine backbone. The nucleobaseε are retained and are bound directly or indirectly to aza nitrogen atomε of the amide portion of the backbone. Repreεentative United Stateε patentε that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5 , 719, 262 , each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al . ,

Science, 1991, 254 , 1497. For the internucleoside linkages, the most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosideε with heteroatom backboneε, and in particular -CH₂-NH-0-CH₂- , - CH₂-N(CH₃) -0-CH_;- [known as a methylene (methylimino) or MMI backbone], -CH_:-0-N(CH₃) -CH₂- , - CH₂-N(CH₃) -N (CH₃) -CH₂- and -0- N(CH₃) -CH₂-CH_:- [wherein the native phoεphodiester backbone is represented as -0-P-0-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Patent 5,034,506.

Conjugates: In attaching an effector group to one or more nucleoεideε or internucleoside linkages of an oligo- nucleotide, various propertieε of the oligonucleotide are modified. An "effector group" iε a chemical moiety that iε capable of carrying out a particular chemical or biological function. Exampleε of εuch effector groupε include, but are not limited to, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic propertieε of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide and other subεtituentε having εimilar propertieε. A variety of chemical linkerε may be uεed to conjugate an effector group to an oligonucleotide of the invention.

The 5 ' and 3 ' termini of an oligonucleotide may be modified to εerve aε point of chemical conjugation of, e . g. , lipophilic moietieε (εee immediately εubεequent paragraph), intercalating agentε (Kuyavin et al . , WO

96/32496, publiεhed October 17, 1996; Nguyen et al . , U.S.

Patent No. 4,835,263, iεsued May 30, 1989) or hydroxyalkyl groups (Helene et al . , WO 96/34008, publiεhed October 31, 1996) .

Other poεitionε within an oligonucleotide of the invention can be uεed to chemically link thereto one or more effector groupε to form an oligonucleotide conjugate. Aε an example, U.S. Patent No. 5,578,718 to Cook et al . diεcloεeε methodε of attaching an alkylthio linker, which may be further derivatized to include additional groupε, to ribofuranoεyl poεitionε, nucleoεidic baεe poεitionε, or on internucleoεide linkages. Additional methods of conjugating oligonucleotides to various effector groups are known in the art; see, e.g., Protocols for Oligonucleotide

Conjugates (Methods in Molecular Biology, Volume 26)

Agrawal, S., ed., Humana Press, Totowa, NJ, 1994. Another preferred additional or alternative modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more lipophilic moieties which enhance the cellular uptake of the oligonucleotide. Such lipophilic moieties may be linked to an oligonucleotide at εeveral different poεitions on the oligonucleotide. Some preferred poεitionε include the 3' poεition of the sugar of the 3' terminal nucleotide, the 5' position of the sugar of the 5' terminal nucleotide, and the 2' position of the sugar of any nucleotide. The N⁶ position of a purine nucleobase may also be utilized to link a lipophilic moiety to an oligonucleotide of the invention (Gebeyehu, G., et al., Nucleic Acids Res., 1987,

15:4513) . Such lipophilic moieties include but are not limited to a cholesteryl moiety (Letsinger et al., Proc. Natl. Acad. Sci. U.S.A., 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306; Manoharan et al . , Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholeεterol (Oberhauεer et al., Nucl . Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl reεidueε (Saiεon-Behmoaraε et al., EMBO J. , 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 255:327; Svinarchuk et al., Biochimie, 1993, 7549), a phospholipid, e.g., di- hexadecyl-rac-glycerol or triethylammonium 1,2-di-O- hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al . , Tetrahedron Lett., 1995, 36:3651; Shea et al . , Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995,

14:969), or adamantane acetic acid (Manoharan et al . ,

Tetrahedron Lett., 1995, 36:3651), a palmityl moiety

(Mishra et al., Biochi . Biophys . Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholeεterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996,

277:923) . Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides, are disclosed in U.S. Patents Nos. 5,138,045, 5,218,105 and 5,459,255, the contentε of which are hereby incorporated by reference.

Repreεentative United Stateε patentε that teach the preparation of εuch oligonucleotide conjugateε include, but are not limited to, U.S. Patentε 4,828,979 4, 948,882

5, 218 105 ^• 5 525 465 • 5 541, 313, 5 545, 730 5,552,538

5 578 717 5 580 731 • 5 580, 731, 5 591, 584 5,109,124

5 118 802 ^■ 5 138 045 ^• 5 414, 077 ^■ 5 486, 603 5,512,439

5 578 718 5 608 046 4 587, 044 4 605 735 4,667, 025

4, 762, 779 4 789, 737 ^• 4, 824, 941, 4, 835, 263 4, 876,335

4, 904 582 • 4 958 013 ^• 5, 082, 830, 5, 112, 963 5,214,136

5 082 830 ^• 5 112 963 • 5 214, 136, 5, 245, 022 5,254,469

5 258 506 ^• 5 262 536 ^• 5 272, 250, 5, 292, 873 5,317, 098

5 371 241 5 391 723 ^• 5 416, 203, 5 451, 463 5,510,475

5 512 667 ^• 5 514 785 • 5 565, 552, ^■ 5 567, 810 5,574,142

5 585 481 ^• 5 587 371 ^• 5 595, 726 ^• 5 597 696 5,599,923

5,599,928 and 5,688,941, certain of which are commonly owned with the preεent application, and each of which iε herein incorporated by reference.

Oligonucleotide Syntheεis: The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Unsubstituted and substituted phosphodiester oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosyεtems model 380B) using εtandard phoεphoramidite chemistry with oxidation by iodine .

Phoεphorothioates are synthesized as per the phosphodieεter oligonucleotideε except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2- benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages . The thiation wait step was increased to 68 sec and was followed by the capping εtep. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 hr) , the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotideε are prepared aε deεcribed in U.S. Patent 5,508,270, herein incorporated by reference .

Alkyl phoεphonate oligonucleotideε are prepared aε deεcribed in U.S. Patent 4,469,863, herein incorporated by reference.

3 ' -Deoxy-3 ' -methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference. Phoεphoramidite oligonucleotideε are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, hereby incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in publiεhed PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively) .

3 ' -Deoxy-3 ' -amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference. Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference .

Boranophosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Methylenemethylimino linked oligonucleosides, alεo identified aε MMI linked oligonucleoεideε, methylenedi- methylhydrazo linked oligonucleoεideε, also identified as MDH linked oligonucleosideε, and methylenecarbonylamino linked oligonucleoεides, alεo identified aε amide-3 linked oligonucleoεideε, and methyleneaminocarbonyl linked oligonucleoεides, also identified as amide-4 linked oligonucleosideε, aε well aε mixed backbone compoundε having, for instance, alternating MMI and PO or PS linkageε are prepared aε deεcribed in U.S. Patentε 5,378,825; 5,386,023; 5,489,677; 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleoεideε are prepared aε deεcribed in U.S. Patentε 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared aε deεcribed in U.S. Patent 5,223,618, herein incorporated by reference.

Peptide nucleic acids (PNAs) are prepared in accordance with any of the variouε procedureε referred to in Peptide Nucleic Acidε (PNA) : Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996, 4, 5. They may also be prepared in accordance with

U.S. Patents 5,539,082; 5,700,922, and 5,719,262, herein incorporated by reference.

Chimeric Oligonucleotides: It is not necesεary for all poεitionε in a given compound to be uniformly modified. In fact, more than one of the aforementioned modificationε may be incorporated in a εingle compound or even at a single nucleoside within an oligonucleotide. The present invention alεo includeε compounds which are chimeric compounds. "Chimeric' compounds or chimeras, ' in the context of this invention, are compounds, particularly oligonucleotideε, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at leaεt one region wherein the oligonucleotide iε modified εo aε to confer upon the oligonucleotide increaεed reεistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.

By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expresεion. Consequently, comparable resultε can often be obtained with εhorter oligonucleotides when chimeric oligonucleotides are uεed, compared to phosphorothioate deoxyoligonucleotides hybridizing to the εame target region. Cleavage of the RNA target can be routinely detected by gel electrophoreεiε and, if neceεεary, aεεociated nucleic acid hybridization techniqueε known in the art .

Chimeric antisense compounds of the invention may be formed as composite structures representing the union of two or more oligonucleotides, modified oligonucleotideε, oligonucleoεides and/or oligonucleotide mimetics aε deεcribed above. Such compoundε have alεo been referred to in the art aε "hybridε" or "gapmerε" . Repreεentative United Stateε patentε that teach the preparation of such hybrid structures include, but are not limited to, U.S. Patents 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065;

5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the preεent application and each of which iε herein incorporated by reference, together with commonly owned and allowed United Stateε patent application εerial number 08/465,880, filed on June 6, 1995, also herein incorporated by reference.

Chimeric oligonucleotideε, oligonucleosides or mixed oligonucleotideε/oligonucleoεideε of the invention can be of several different types. These include a first type wherein the "gap' segment of linked nucleosideε iε poεitioned between 5' and 3' "wing' segments of linked nucleosides and a εecond "open end' type wherein the "gap' εegment is located at either the 3 ' or the 5 ' terminus of the oligomeric compound. Oligonucleotideε of the first type are alεo known in the art aε "gapmers ' or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers ' or "wingmers . '

[2 ' -O-Me] -- [2 ' -deoxy] -- [2 ' -O-Me] Chimeric Phoεphorothioate Oligonucleotides: Chimeric oligonucleotides having 2 ' -0-alkyl phosphorothioate and 2'- deoxy phosphorothioate oligonucleotide segmentε are εynthesized using 2 ' -deoxy-5 ' -dimethoxytrityl-3 ' -0- phosphoramidites for the DNA portion and 5 ' -dimethoxy- trityl-2 ' -O-methyl-3 ' -O-phosphoramidites for 5' and 3' wings. The standard synthesis cycle is modified by increaεing the wait εtep after the delivery of tetrazole and base to 600 s repeated four timeε for DNA and twice for 2 '-0-methyl. The fully protected oligonucleotide waε cleaved from the support and the phoεphate group iε deprotected in 3:1 Ammonia/Ethanol at room temperature overnight then lyophilized to dryness . Treatment in methanolic ammonia for 24 hrs at room temperature is done to deprotect all bases and the samples are again lyophilized to dryness.

[2 ' -0- (2-Methoxyethyi) ] -- [2 ' -deoxy] -- [2 ' -0- (Methoxyethyl ] Chimeric Phosphorothioate Oligonucleotides: [2 ' -0- (2-methoxyethyi) ] -- [2 ' -deoxy] -- [-2 ' -0- (methoxyethyi) ] chimeric phosphorothioate oligonucleotides are prepared as per the procedure above for the 2 ' -0-methyl chimeric oligonucleotide, with the substitution of 2 ' -0- (methoxyethyi) amidites for the 2 ' -0-methyl amiditeε.

[2 ' -0- (2-methoxyethyi) phosphodieεter] -- [2 ' -deoxy phoεphorothioate] -- [2 ' -0- (2-Methoxyethyi) Phoεphodiester]

Chimeric Oligonucleotide: [2 ' -0- (2-methoxyethyi phosphodiester] -- [2 ' -deoxy phosphorothioate] -- [2 ' -0-

(methoxyethyl) phosphodiester] chimeric oligonucleotideε are prepared as per the above procedure for the 2 ' -0-methyl chimeric oligonucleotide with the substitution of 2 ' -0-

(methoxyethyi) amidites for the 2 ' -0-methyl amidites in the wing portions. Sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) is used to generate the phosphorothioate internucleotide linkages within the wing portions of the chimeric structureε.

Oxidization with iodine is used to generate the phosphodieεter internucleotide linkageε for the center gap.

Other chimeric oligonucleotideε, chimeric oligo- nucleosides and mixed chimeric oligonucleotides/oligo- nucleosideε are εynthesized according to United Stateε Patent 5,623,065, herein incorporated by reference.

The present invention also includes oligonucleotides that are substantially chirally pure with regard to particular poεitions within the oligonucleotides. Examples of εubεtantially chirally pure oligonucleotideε include, but are not limited to, thoεe having phoεphorothioate linkageε that are at leaεt 75% Sp or Rp (Cook et al., U.S.

Patent No. 5,587,361) and thoεe having εubεtantially chirally pure (Sp or Rp) alkylphoεphonate, phoεphoamidate or phoεphotriester linkages (Cook, U.S. Patents Nos. 5,212,295 and 5,521,302).

Examples of specific oligonucleotides and the target genes to which they inhibit which may be employed in formulations of the present invention include:

ISIS- -15839 GCCCA AGCTG GCATC CGTCA (SEQ ID NO:l) ICAM-1

ISIS- -13312 GCGTT TGCTC TTCTT CTTGC G (SEQ ID NO: 2) HCMV

ISIS- -9605 GTTCT CGCTG GTGAG TTTCA (SEQ ID NO:3) PKC

ISIS- -9606 GTTCT CGCTG GTGAG TTTCA (SEQ ID NO:3) PKCα

ISIS- -14859 AACTT GTGCT TGCTC (SEQ ID NO:4) PKCα

ISIS- -17709 GCCAA GGAGT TTGAG ATAGT (SEQ ID NO: 5) akt-2

ISIS- -17044 CCGCA GCCAT GCGCT CTTGG (SEQ ID NO: 6) VLA-4

ISIS- -28089 GTGTG CCAGA CACCC TATCT (SEQ ID NO: 7) TNFα

ISIS- -104838 GCTGA TTAGA GAGAG GTCCC (SEQ ID NO: 8) TNFα

wherein (i) each oligo backbone linkage is a phosphorothioate linkage (except ISIS-9605 and ISIS-17709) and (ii) each sugar iε 2 '-deoxy unleεε represented in bold font in which case it incorporates a 2 ' -0-methoxyethyi group and (iii) underlined cytosine nucleosides incorporate a 5-methyl substituent on their nucleobase. ISIS-9605 incorporateε natural phosphodiester bonds at the first five and last five linkages with the remainder being phosphorothioate linkageε. ISIS-17709 incorporateε natural phosphodiester bonds at the first four and last four linkages with the remainder being phosphorothiate linkage .

The formulation of pharmaceutical compoεitionε and their subsequent administration is believed to be within the εkill of those in the art. Specific comments regarding the present invention are presented below.

Therapeutic Considerations: In general, for therapeutic applications, a patient (i.e., an animal, including a human, having, suεpected of having, or prediεposed to a disease or disorder) iε adminiεtered one or more nucleic acidε, including oligonucleotideε, in accordance with the invention in doεeε ranging from 0.01 ug to 100 g per kg of body weight depending on the age of the patient and the εeverity of the diεorder or disease state being treated. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular diεeaεe or diεorder, itε severity and the overall condition of the patient, and may extend from once daily to once every 20 years. In the context of the invention, the term "treatment" or "treatment regimen" is meant to encompasε therapeutic, palliative and prophylactic modalities. Following treatment, the patient is monitored for changes in his/her condition and for alleviation of the symptomε of the diεorder or diεease state. The dosage of the nucleic acid may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptomε of the disorder or disease εtate iε obεerved, or if the diεorder or diεease εtate haε been ablated. Doεing iε dependent on εeverity and reεponεiveness of the disease state to be treated, with the course of treatment laεting from εeveral dayε to εeveral monthε, or until a cure iε effected or a diminution of the diεeaεe εtate iε achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Personε of ordinary εkill can eaεily determine optimum doεageε, doεing methodologieε and repetition rates. Optimum dosageε may vary depending on the relative potency of individual oligonucleotideε, and can generally be estimated based on EC₅₀s found to be effective in in vi tro and in vivo animal models. In general, dosage iε from 0.01 μg to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 yearε . An optimal doεing εchedule iε uεed to deliver a therapeutically effective amount of the nucleic acid being administered via a particular mode of administration.

The term "therapeutically effective amount, " for the purposes of the invention, refers to the amount of nucleic acid-containing formulation which is effective to achieve an intended purpose without undeεirable εide effects (such as toxicity, irritation or allergic responεe) . Although individual needs may vary, determination of optimal rangeε for effective amountε of formulations is within the εkill of the art. Human doεeε can be extrapolated from animal studies (Katocs et al . , Chapter 27 In : Remington ' s Pharmaceutical Sciences , 18th

Ed., Gennaro, ed., Mack Publiεhing Co., Easton, PA, 1990) . Generally, the dosage required to provide an effective amount of a formulation, which can be adjusted by one skilled in the art, will vary depending on the age, health, physical condition, weight, type and extent of the diseaεe or diεorder of the recipient, frequency of treatment, the nature of concurrent therapy (if any) and the nature and εcope of the deεired effect (ε) (Nieε et al . , Chapter 3 In :

Goodman & Gilman ' s The Pharmacological Basis of Therapeutics , 9th Ed., Hardman et al . , edε . , McGraw-Hill,

New York, NY, 1996) .

Aε uεed herein, the term "high riεk individual" iε meant to refer to an individual for whom it haε been determined, via, e.g., individual or family hiεtory or genetic teεting, haε a εignificantly higher than normal probability of being εuεceptible to the onset or recurrence of a disease or disorder. As art of treatment regimen for a high risk individual, the individual can be prophylactically treated to prevent the onset or recurrence of the disease or disorder. The term "prophylactically effective amount" is meant to refer to an amount of a formulation which produces an effect observed as the prevention of the onεet or recurrence of a diεease or disorder. Prophylactically effective amountε of a formulation are typically determined by the effect they have compared to the effect obεerved when a εecond formulation lacking the active agent iε administered to a similarly situated individual.

Following succeεεful treatment, it may be deεirable to have the patient undergo maintenance therapy to prevent the recurrence of the diεeaεe state, wherein the nucleic acid is adminiεtered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years. For example, in the caεe of in individual known or εuεpected of being prone to an autoimmune or inflammatory condition, prophylactic effects may be achieved by administration of preventative doses, ranging from C.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years. In like fashion, an individual may be made less susceptible to an inflammatory condition that is expected to occur as a result of some medical treatment, e.g., graft versuε hoεt diεease resulting from the transplantation of cells, tiεsue or an organ into the individual .

The compositionε of the preεent invention can include εterile aqueouε εolutionε which may alεo contain buffers, diluents and other εuitable additiveε.

The pharmaceutical formulations, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniqueε well known in the pharmaceutical induεtry. Such techniqueε include the εtep of bringing into association the active ingredients with the pharmaceutical carrier (s) or excipient (s) . In general the formulations are prepared by uniformly and intimately bringing into asεociation the active ingredientε with liquid carrierε or finely divided εolid carrierε or both.

5. Bioequivalents

A. Pharmaceutically Acceptable Salts: The compoundε of the invention encompass any pharmaceutically acceptable salts, esters, or εaltε of such esterε, or any other compound which, upon adminiεtration to an animal including a human, iε capable of providing (directly or indirectly) the biologically active metabolite or reεidue thereof. Accordingly, for example, the disclosure is also drawn to "pharmaceutically acceptable salts" of the penetration enhancers and nucleic acids of the invention and prodrugs of εuch nucleic acidε. "Pharmaceutically acceptable εaltε" are phyεiologically and pharmaceutically acceptable salts of the penetration enhancers and nucleic acids of the invention: i.e., salts that retain the deεired biological activity of the parent compound and do not impart undeεired toxicological effectε thereto. The term "pharmaceutically acceptable εaltε" referε to phyεiologically and pharmaceutically acceptable salts of the oligonucleotide and nucleic acid compounds employed in the compositionε of the preεent invention (i.e., εaltε that retain the deεired biological activity of the parent compound and do not impart undeεired toxicological effectε thereto) .

Pharmaceutically acceptable baεe addition εaltε are formed with metalε or amineε, εuch aε alkali and alkaline earth metalε or organic amineε. Exampleε of metals used as cations are εodium, potaεsium, magnesium, calcium, ammonium, polyamines εuch as spermine and εpermidine, and the like. Exampleε of suitable amineε are chloroprocaine, choline, N,N' -dibenzylethylenediamine, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (εee, for example, Berge et al . , "Pharmaceutical Salts," J. of Pharma Sci . , 1977,

66:1) . The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the deεired baεe to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and iεolating the free acid in the conventional manner. The free acid forms differ from their reεpective εalt formε εomewhat in certain physical properties such as solubility in polar solvents, but otherwise the saltε are equivalent to their respective free acid for purposes of the present invention.

B. Oligonucleotide Prodrugs:

The oligonucleotideε of the invention may additionally or alternatively be prepared to be delivered in a "prodrug" form. The term "prodrug" indicates a therapeutic agent that iε prepared in an inactive form that iε converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versionε of the oligonucleotideε of the invention are prepared as SATE [ (S-acetyl-2-thioethyl) phosphate] derivatives according to the methodε disclosed in WO 93/24510 to Gosselin et al . , published December 9, 1993.

C. Oligonucleotide Deletion Derivatives:

During the process of oligonucleotide synthesis, nucleoεide monomerε are attached to the chain one at a time in a repeated εerieε of chemical reactions such as nucleoside monomer coupling, oxidation, capping and detritylation. The stepwise yield for each nucleoside addition iε above 99%. That meanε that leεε than 1% of the sequence chain failed to the nucleoside monomer addition in each step as the total resultε of the incomplete coupling followed by the incomplete capping, detritylation and oxidation (Smith, Anal . Chem . , 1988, 60 , 381A) . All the shorter oligonucleotides, ranging from (n-1) , (n-2) , etc., to 1- mers (nucleotideε) , are preεent as impurities in the n-mer olignucleotide product. Among the impurities, (n-2)-mer and shorter oligonucleotide impuritieε are preεent in very εmall amounts and can be easily removed by chromatographic purification (Warren et al . , Chapter 9 In : Methods in Molecular Biology, Vol . 26 : Protocols for Oligonucleotide

Conjuga tes , Agrawal, S., Ed., 1994, Humana Press Inc., Totowa, NJ, pageε 233-264) . However, due to the lack of chromatographic εelectivity and product yield, some (n-1) -mer impuritieε are εtill preεent in the full-length (i.e., n-mer) oligonucleotide product after the purification process. The (n-1) portion consists of the mixture of all possible single base deletion sequenceε relative to the n-mer parent oligonucleotide. Such (n-1) impuritieε can be claεεified aε terminal deletion or internal deletion sequences, depending upon the position of the misεing baεe (i.e., either at the 5' or 3 ' terminuε or internally) . When an oligonucleotide containing εingle baεe deletion εequence impuritieε is used as a drug (Crooke, Hematologic Pathology, 1995, 9 , 59), the terminal deletion εequence impurities will bind to the same target mRNA as the full length sequence but with a εlightly lower affinity. Thus, to some extent, such impurities can be considered as part of the active drug component, and are thus considered to be bioequivalents for purpoεeε of the present invention. 6. Exemplary Utilities of the Invention:

The compoεitionε and methodε of the preεent invention are useful for the treatment of a wide variety of disorders including asthma, cancers of the lung, pulmonary fibrosis, and various infectiouε diεeaεeε of the lung, including rhinoviruε , tuberculoεiε, bronchitiε, and pneumonia .

Two important eventε that occur at the cellular level and which contribute to aεthmatic responses are (1) the infiltration of the airway lumen by leukocytes and (2) the activation of T lymphocytes (T cells) from the T_H0 to the T_H2 state and the subεequent production and releaεe of pro-inflammatory cytokineε by activated T cells. Molecules that mediate either or both of theεe processes are potential targets for aεthma therapy. ICAM-1 haε been implicated in the pathogenesis of asthma, and a monoclonal antibody to ICAM-1 attenuates eosinophilia and hyperreεponεivenesε (Wegner et al . , Science, 1990, 247, 456) . Antisenεe compoundε targeted to

ICAM-1 are deεcribed in U.S. Patentε No . 5,514,788 and 5,591,623, and copending U.S. patent applicationε Serial Noε. 09/009,490 and 09/062,416, January 20, 1998 and April 17, 1998, reεpectively, all to Bennett et al . , each of which are incorporated herein their entirety.

Adhesion molecule-mediated recruitment of eosinophilε and other leukocyteε haε been implicated in mechanisms of asthmatic inflammation (Bochner et al . , Annu . Rev. Immunol . , 1994, 12, 295). In addition to ICAM-1, adheεion molecules of particular interest include ELAM-1 (a.k.a. E-εelectin) andVCAM-1. Antibody to ELAM-1 preventε neutrophil accumulation in monkey lungs (Gundel et al . , J. Clin . Inves t . , 1991, 88, 1407). Antisenεe compoundε targeted to the adhesions molecules ELAM-1 and VCAM-1 are described in U.S. Patents Nos. 5,514,788 and 5,591,623.

It has been hoped that inhibitors of ICAM-1, VCAM-1, and ELAM-1 expression woud provide a novel therapeutic class of anti-inflammatory agents with activity towards a wide variety of inflammaotry diεeaεes, or diseaεeε within inflammatory component εuch aε asthma. The use of neutralizing monoclonal antibodies against ICAM-1 in animal models provide ample evidence that such inhibitors if identified would have therapeutic benefit for aεthma. See Wegner et al . , Science 1990, 247, 456-459.

B7-1 and B7-2 are thought to be the primary moleculeε expreεεed on professional antigen presenting cells, (APCs) (εee Liu and Linεley, Curr. Opin . Immunol . , 1992, 4, 265) . The B7 proteinε are thought to provide an eεεential εignal for differentiation of T cells (T_H0 lymphocytes) and to contribute to the activation of memory cells . Antisenεe compounds targeted to B7 proteins are deεcribed in copending U.S. patent application Serial No. 08/777,266, filed December 31, 1996, to Bennett et al .

Another molecule expreεεed on APCε and which εtimulateε T cell activation is CD40 (for a review, see Banchereau et al . , Annu . Rev. Immunol . , 1994, 12 , 881) .

Antisenεe compoundε targeted to CD40 are described in copending U.S. patent application Serial No. 09/071,433, filed May 1, 1998, to Bennett et al .

Yet another molecule expressed on APCs and which εtimulateε T cell activation iε LFA-3 (see Liu and Linsley, Curr. Opin . Immunol . , 1992, 4, 265). Antiεenεe compoundε targeted to LFA-3 are described in copending U.S. patent application Serial No. 09/045,106, filed March 20, 1998, to Bennett et al .

PECAM-1 proteins are glycoproteins which are expresεed on the εurfaceε of a variety of cell typeε (for reviewε, εee Newman, J. Clin . Invest . , 1997, 99 , 3 and DeLiεεer et al . , Immunol . Today, 1994, 15, 490). In addition to directly participating in cell-cell interactions, PECAM-1 apparently alεo regulates the activity and/or expression of other molecules involved in cellular interactions (Litwin et al . , J. Cell Biol . , 1997, 139 , 219) and iε thuε a key mediator of εeveral cell: cell interactions. Antisenεe compoundε targeted to PECAM-1 are deεcribed in copending U.S. patent application Serial No. 09/044,506, filed March 19, 1998, to Bennett et al .

The compoεitions and methods of the present invention are uεeful for the treatment of cancers of the lung. For example, antisense oligonucleotides directed to any of a number of molecular targetε involved in tumorigeneεiε, maintenance of the hyperproliferative state and metaεtaεis can targeted to prevent or inhibit lung cancers, or tc prevent their spread to other tiεsueε.

The ras oncogeneε are guanine-binding proteinε that have been implicated in cancer by, e.g., the fact that activated ras oncogenes have been found in about 30% of human tu orε generally; thiε figure approached 100% in carcinomaε of the exocrine pancreaε (for a review, see

Downward, Trends in Biol . Sci . , 1990, 15, 469). Further, 99/60166

43

intratracheal installation of a retroviral antisense K-ras construct prevents orthotopic human lung cancer growth in an animal model, demonstrating the potential of antisense appraoches to lung cancer (Georges, R.N., et al., Cancer Research, 1993, 53, 1743). Antisense compounds targeted to

H-ras and K-ras are described in U.S. Patent No. 5,582,972 to Lima et al . , 5,582,986 to Monia et al . and 5,661,134 to

Cook et al . , and in published PCT application WO 94/08003, the disclosures of which are incorporated by reference herein in their entirety.

Protein Kinase C (PKC) proteins have also been implicated in tumorigenesis . Antisense compounds targeted to Protein Kinase C (PKC) proteins are described in U.S. Patents Nos. 5,620,963 to Cook et al . and 5,681,747 to Boggs et al .

The compositions and methods of the present invention are useful for the treatment of Pulmonary Fibrosis. Phan { Thorax, 1995, 50, 415) reviews current beliefs regarding pulmonary fibrosis, and notes that potential targets for therapy include cell adhesion and/or T cell stimulatory molecules (e.g., ICAM-1, ELAM-1, VCAM-1,

B7 proteins, CD40, LFA-3, PECAM-1, supra) . Antisense oligonucleotides targeted for one or more of these proteins are amenable for use in the compositions and methods of the invention.

The compositions and methods of the present invention also find use in the treatment and/or prevention of rhinovirus. For example, it has been proposed that ICAM-1 is the cellular receptor for the major serotype of rhinovirus, which accounts for greater than 50% of common colds (Staunton et al . , Cell , 1989, 56, 849; Greve et al . ,

Cell , 1989, 56, 839) .

The compositions and methods of the present invention also find use in the treatment of tuberculosis. For example, antisense compounds targeted to the pathogens Mycobacterium tuberculosis ox M. bovis can be administered to a patient in accordance with the methods of the invention.

In instances where acute bronchitis is a result of infection, bronchitis can be treated by administration in accordance with the methods of the invention of compositions of the invention containing one or more antisense compounds targeted to the appropriate pathogen (s) .

The compositions and methods of the present invention also find use in the treatment of pneumonia, for example by administration of antisense compounds targeted to the pathogen Streptococcus pneumoniae.

In addition to the foregoing, the methods and compositions of the invention are also directed to antisense oligonucleotides targeted to genes that are implicated in other lung disorders. These include, for example, viruses which infect the lung (e.g. respiratory syncytial virus, H. Influenzae, parainfluenza) , obstructive lung disorders such as pulmonary embolism or anaphylaxis, chronic obstructive pulmonary disease (COPD) , emphysema, chronic bronchitis, bronchiectasis and cystic fibrosis.

The invention is drawn to the pulmonary administration of a nucleic acid, such as an oligonucleotide, having biological activity to an animal. By "having biological activity, " it is meant that the nucleic acid functions to modulate the expression of one or more genes in an animal as reflected in either absolute function of the gene (such as ribozyme activity) or by production of proteins coded by such genes. In the context of this invention, "to modulate" means to either effect an increase (stimulate) or a decrease (inhibit) in the expression of a gene. Such modulation can be achieved by, for example, an antisense oligonucleotide by a variety of mechanisms known in the art, including but not limited to transcriptional arrest; effects on RNA processing (capping, polyadenylation and splicing) and transportation; enhancement or reduction of cellular degradation of the target nucleic acid; and translational arrest (Crooke et al . , Exp . Opin . Ther. Patents , 1996, 6:1).

In an animal other than a human, the compositionε and methodε of the invention can be used to study the function of one or more genes in the animal. For example, antisenεe oligonucleotideε have been εyεtemically adminiεtered to ratε in order to εtudy the role of the N- methyl-D-aεpartate receptor in neuronal death, to mice in order to inveεtigate the biological role of protein kinaεe C-a, and to ratε in order to examine the role of the neuropeptide Yl receptor in anxiety (Wahleεtedt et al . ,

Nature, 1993, 363:260; Dean et al . , Proc. Natl . Acad. Sci .

U. S .A . , 1994, 91:11762; and Wahlestedt et al . , Science,

1993, 259:528, respectively). In instances where complex families of related proteins are being investigated, "antiεenεe knockoutε" (i.e., inhibition of a gene by εyεtemic adminiεtration of antiεense oligonucleotides) may represent the most accurate means for examining a specific member of the family (see, generally, Albert et al . , Trends

Pharmacol . Sci . , 1994, 15:250). The compositions and methods of the invention are also useful therapeutically, i.e., to provide therapeutic, palliative or prophylactic relief to an animal, including a human, having or suspected of having or of being suεceptible to, a diεeaεe or diεorder that iε treatable in whole or in part with one or more nucleic acidε . The term "diεeaεe or disorder" (1) includes any abnormal condition of an organiεm or part, eεpecially aε a conεequence of infection, inherent weakness, environmental stress, that impairs normal physiological functioning; (2) excludes pregnancy per se but not autoimmune and other diεeases aεεociated with pregnancy; and (3) includes cancers and tumors. The term "having or suspected of having or of being susceptible to" indicates that the subject animal has been determined to be, or is εuεpected of being, at increased risk, relative to the general population of such animalε, of developing a particular disease or disorder aε herein defined. For example, a εubject animal could have a perεonal and/or family medical hiεtory that includes frequent occurrences of a particular diεease or disorder. As another example, a subject animal could have had such a suεceptibility determined by genetic screening according to techniques known in the art (see, e.g., U.S. Congress,

Office of Technology Asseεsment, Chapter 5 In : Genetic

Moni toring and Screening in the Workplace, OTA-BA-455, U.S.

Government Printing Office, Washington, D.C., 1990, pages 75-99) . The term "a diseaεe or disorder that is treatable in whole or in part with one or more nucleic acids" refers to a diseaεe or diεorder, aε herein defined, (1) the management, modulation or treatment thereof, and/or (2) therapeutic, palliative and/or prophylactic relief therefrom, can be provided via the adminiεtration of more nucleic acidε . In a preferred embodiment, εuch a diεease or disorder iε treatable in whole or in part with an antiεenεe oligonucleotide.

Preferably, the compounds and method of the invention employ particles containing oligonucleotide therapeutics or diagnostics. The particles can be solid or liquid, and are preferably of respirable εize: that iε, particleε of a εize εufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. In general, particles ranging from about 5 to 20 microns in size are respirable and are expected to reach the bronchioles (Allen, Secundum Artem,

Vol. 6, No. 3, on-line publication updated May 8, 1998, and available at http://www.paddocklabs.com/secundum/ secarndx.html; . It is greatly desirable to avoid particles of non-respirable εize, aε these tend to deposit in the throat and be εwallowed, thus reducing the quantity of oligonucleotide reaching the lung.

Liquid pharmaceutical compositionε of oligonucleotide can be prepared by combining the oligonucleotide with a εuitable vehicle, for example εterile pyrogen free water, or εaline εolution. Other therapeutic compounds may optionally be included.

The preεent invention also contemplates the use of solid particulate compositionε. Such compoεitionε preferably compriεe particleε of oligonucleotide that are of reεpirable εize. Such particleε can be prepared by, for example, grinding dry oligonucleotide by conventional meanε, fore example with a mortar and peεtle, and then paεεing the reεulting powder compoεition through a 400 meεh screen to segregate large particleε and agglomerates. A solid particulate composition comprised of an active oligonucleotide can optionally contain a diεperεant which serves to facilitate the formation of an aerosol, for example lactose.

In accordance with the methods of the present invention, oligonucleotide compositions are aerosolized. Aerosolization of liquid particleε can be produced by any εuitable means, such aε with a nebulizer. See, for example, U.S. Patent No. 4,501,729. Nebulizerε are commercially available devices which transform εolutions or suεpenεions into a therapeutic aerosol mist either by meanε of acceleration of a compreεεed gaε, typically air or oxygen, through a narrow venturi orifice or by meanε of ultraεonic agitation. Suitable nebulizerε include thoεe sold by Blairex^* under the name PARI LC PLUS, PARI DURA-NEB 2000, PARI-BABY Size, PARI PRONEB Compresεor with LC PLUS, PARI WALKHALER Compreεεor/Nebulizer Syεtem, PARI LC PLUS Reuεable Nebulizer, and PARI LC Jet+ ^®Nebulizer.

Exemplary formulationε for use in nebulizers conεiεt of an oligonucleotide in a liquid, such as εterile, pyragen free water, or εaline εolution, wherein the oligonucleotide compriεes up to about 40% w/w of the formulation. Preferably, the oligonucleotide compriseε leεε than 20% w/w. If deεired, further additives such as preservativeε (for example, methyl hydroxybenzoate) antioxidants, and flavoring agents can be added to the composition.

Solid particles compriεing an oligonucleotide can alεo be aeroεolized uεing any εolid particulate medicament aerosol generator known in the art . Such aerosol generatorε produce reεpirable particleε, aε described above, and further produce reproducible metered dose per unit volume of aerosol. Suitable solid particulate aerosol generators include insufflators and metered dose inhalers. Metered dose inhalers suitable fore used in the art (along with the trade name, manufacturer and indication they are uεed for) and uεeful in the preεent invention include:

Delivery Device Trade name Manufacturer Indication Metered Dose Inhaler (MDI)

Alupent- Boehringer Ingelheim Beta- adrenergic bronchodilator

Atrovent- Boehringer Ingelheim Anticholinergic bronchodilator Aerobid, Aerobid-M - Foreεt Steriodal Anti- inflammatory

Beclovent, Beconaεe - Glaxo Wellcome Steriodal Anti-inflammatory

Flovent - Glaxo Wellcome Steriodal Anti- inflammatory

Ventolin - Glaxo Wellcome Beta-adrenergic bronchodilator

Proventil - Key Pharm. Beta-adrenergic bronchodilator Maxair - 3M Pharm. Beta-adrenergic bronchodilator

Azmacort - Rhone-Poulenc Rorer Steriodal Anti-inflammatory

Tilade - Rhone-Poulenc Rorer Anti-inflammatory (inhibitε release of inflammatory mediators)

Intal - Rhone-Poulenc Rorer Inhibits mast cell degranulation (Asthma) Vanceril - Schering Steriodal Anti- inflammatory

Tornalate - Dura Pharm. Beta-adrenergic bronchodilator

Solutions for Nebulization

Alupent- Boehringer Ingelheim Beta- adrenergic bronchodilator

Pulmozyme - Genetech Recombinant human deoxyribonucleaεe I

Ventolin - Glaxo Wellcome Beta-adrenergic bronchodilator

Tornalate - Dura Pharm. Beta-adrenergic bronchodilator Intal - Rhone-Poulenc Rorer Inhibitε maεt cell degranulation (Aεthma)

Capsules (powder) for inhalation Ventolin - Glaxo Wellcome

(Rotocapε for uεe in Rotohaler device) Beta-adrenergic bronchodilator

Powder for inhalation

Pulmicort - Aεtra USA (Turbuhaler device) Steriodal Anti-inflammatory

Preferably, liquid or εolid aerosols are produced at a rate of from about 10 to 150 liters per minute, more preferably from about 30 to 150 liters per minute, and most preferably about 60 liters per minute. Aε used herein, the term "alkyl" includes but is not limited to straight chain, branch chain, and alicyclic hydrocarbon groups. Alkyl groups of the present invention may be substituted. Representative alkyl substituents are discloεed in United States Patent No. 5,212,295, at column 12, lines 41-50.

Further representative 2 ' sugar modifications amenable to the present invention include fluoro, O-alkyl, O-alkylamino, O-alkylalkoxy, protected O-alkylamino, O-alkylaminoalkyl, O-alkyl imidazole, and polyethers of the formula (0-alkyl)_m, where m is 1 to about 10. Preferred among these polyetherε are linear and cyclic polyethylene glycolε (PEGs) , and (PEG) -containing groups, such as crown ethers and those which are discloεed by Ouchi, et al . , Drug Design and Discovery 1992, 9, 93, Ravasio, et al . , J. Org.

Chem . 1991, 56, 4329, and Delgardo et. al . , Cri tical

Reviews in Therapeutic Drug Carrier Systems 1992, 9, 249, each of which are hereby incorporated by reference in their entirety. Further sugar modifications are disclosed in Cook, P.D., supra . Fluoro, O-alkyl, O-alkylamino, O-alkyl imidazole, O-alkylaminoalkyl, and alkyl amino subεtitution iε deεcribed in United Stateε Patent Application εerial number 08/398,901, filed March 6, 1995, entitled Oligomeric Compoundε having Pyrimidine Nucleotide (s) with 2' and 5' Subεtitutionε, hereby incorporated by reference in itε entirety.

Sugarε having 0-substitutions on the ribosyl ring are also amenable to the present invention. Representative subεtitutionε for ring 0 include S, CH₂, CHF, and CF₂, εee, e.g., Secrist, et al . , Abstract 21 , Program & Abstracts,

Tenth International Roundtable, Nucleosides, Nucleotides and their Biological Applications, Park City, Utah, Sept.

16-20, 1992, hereby incorporated by reference in its entirety. As used herein, the term "aralkyl" denotes alkyl groups which bear aryl groups, for example, benzyl groups. The term "alkaryl" denotes aryl groups which bear alkyl groups, for example, methylphenyl groups. "Aryl" groupε are aromatic cyclic compounds including but not limited to phenyl, naphthyl, anthracyl, phenanthryl, pyrenyl, and xylyl .

In general, the term "hetero" denotes an atom other than carbon, preferably but not exclusively N, 0, or S. Accordingly, the term "heterocycloalkyl" denotes an alkyl ring εystem having one or more heteroatoms (i.e., non-carbon atoms) . Preferred heterocycloalkyl groups include, for example, morpholino groups. As used herein, the term "heterocycloalkenyl" denotes a ring εystem having one or more double bondε, and one or more heteroatomε . Preferred heterocycloalkenyl groupε include, for example, pyrrolidino groupε .

In some preferred embodiments, the compounds of the invention can compriεe a linker connected to a solid support . Solid supportε are εubstrates which are capable of εerving aε the solid phaεe in solid phase synthetic methodologies, such as thoεe deεcribed in Carutherε U.S.

Patents Nos. 4,415,732; 4,458,066; 4,500,707; 4,668,777; 4,973,679; and 5,132,418; and Koεter U.S. Patentε Nos. 4,725,677 and Re. 34,069. Linkers are known in the art aε short molecules which serve to connect a solid support to functional groups (e.g., hydroxyl groups) of initial synthon molecules in εolid phaεe εynthetic techniqueε. Suitable linkers are disclosed in, for example, Oligonucleotides And Analogues A Practical Approach,

Ekstein, F. Ed., IRL Press, N.Y, 1991, Chapter 1, pages 1- 23, hereby incorporated by reference in its entirety.

Solid supports according to the invention include those generally known in the art to be suitable for use in solid phase methodologies, including, for example, controlled pore glass (CPG) , oxalyl-controlled pore glasε { see, e . g. , Alul, et al . , Nucleic Acids Research 1991, 19,

1527, hereby incorporated by reference in itε entirety) , TentaGel Support -- an aminopolyethyleneglycol derivatized εupport (see, e.g., Wright, et al . , Tetrahedron Letters 1993, 34 , 3373, hereby incorporated by reference in its entirety) and Poros -- a copolymer of polystyrene/divinylbenzene .

Some preferred embodiments of the invention comprise one or more hydroxyl protecting groupε . A wide variety of hydroxyl protecting groupε can be employed in the methodε of the invention. Preferably, the protecting group iε εtable under baεic conditionε but can be removed under acidic conditionε. In general, protecting groupε render chemical functionalities inert to specific reaction conditions, and can be appended to and removed from such functionalities in a molecule without substantially damaging the remainder of the molecule. Representative hydroxyl protecting groups are discloεed by Beaucage, et al . , Tetrahedron 1992, 48, 2223-2311, and also in Greene and Wuts, Protective Groups in Organic Synthesis , Chapter

2, 2d ed, John Wiley & Sonε, New York, 1991, each of which are hereby incorporated by reference in their entirety. Preferred protecting groupε uεed for R₂, R₃ and R_3a include dimethoxytrityl (DMT) , monomethoxytrityl, 9-phenylxanthen- 9-yl (Pixyl) and 9- (p-methoxyphenyl) xanthen-9-yl (Mox) . The R₂ or R₃ group can be removed from oligomeric compounds of the invention by techniqueε well known in the art to form the free hydroxyl. For example, dimethoxytrityl protecting groups can be removed by protic acids such aε formic acid, dichloroacetic acid, trichloroacetic acid, p- toluene sulphonic acid or with Lewis acids such as for example zinc bromide. See for example, Greene and Wutε, supra . In some preferred embodiments of the invention amino groups are appended to alkyl or other groups, such as, for example, 2 ' -alkoxy groupε (e.g., where R_τ iε alkoxy) . Such amino groups are also commonly present in naturally occurring and non-naturally occurring nucleobaseε. It iε generally preferred that theεe amino groups be in protected form during the synthesis of oligomeric compounds of the invention. Representative amino protecting groupε suitable for these purposes are discuεεed in Greene and Wutε, Protective Groups in Organic

Synthesis, Chapter 7, 2d ed, John Wiley & Sonε, New York,

1991. Generally, as used herein, the term "protected" when used in connection with a molecular moiety such as

"nucleobase" indicates that the molecular moiety contains one or more functionalities protected by protecting groups . The oligomeric compounds of the invention can be used in diagnoεticε, therapeutics and as research reagents and kits. They can be used in pharmaceutical compositions by including a suitable pharmaceutically acceptable diluent or carrier. They further can be used for treating organismε having a diεeaεe characterized by the undeεired production of a protein. The organiεm εhould be contacted with an oligonucleotide having a sequence that is capable of specifically hybridizing with a strand of nucleic acid coding for the undeεirable protein. Treatmentε of this type can be practiced on a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms. Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of itε hereditary, metabolic or cellular control iε susceptible to therapeutic and/or prophylactic treatment in accordance with the invention. Seemingly diverse organismε εuch as bacteria, yeast, protozoa, algae, all plants and all higher animal forms, including warm-blooded animals, can be treated. Further, each cell of multicellular eukaryotes can be treated, as they include both DNA-RNA tranεcription and RNA-protein tranεlation aε integral partε of their cellular activity.

Furthermore, many of the organelleε (e.g., mitochondria and chloroplaεtε) of eukaryotic cells also include transcription and translation mechanisms. Thus, single cells, cellular populationε or organelleε can also be included within the definition of organisms that can be treated with therapeutic or diagnostic oligonucleotides. EXAMPLES

The following examples illustrate the invention and are not intended to limit the same. Those skilled in the art will recognize, or be able to ascertain through routine experimentation, numerous equivalents to the specific subεtanceε and procedureε deεcribed herein. Such equivalentε are conεidered to be within the scope of the present invention.

Example 1: Preparation of Oligonucleotides A. General Synthetic Techniques:

Oligonucleotides were synthesized on an automated DNA syntheεizer using standard phosphoramidite chemistry with oxidation using iodine. Beta-cyanoethyldiiεopropyl phoεphoramiditeε were purchased from Applied Bioεyεtemε (Foεter City, CA) . For phoεphorothioate oligonucleotideε, the εtandard oxidation bottle waε replaced by a 0.2 M solution of 3H-1, 2-benzodithiole-3-one-l, 1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages . The syntheεiε of 2 '-O-methyl- (a.k.a. 2 ' -methoxy-

) phoεphorothioate oligonucleotideε iε according to the procedureε set forth above subεtituting 2 ' -O-methyl b- cyanoethyldiisopropyl phosphoramidites (Chemgenes, Needham, MA) for standard phoεphoramiditeε and increaεing the wait cycle after the pulse delivery of tetrazole and baεe to 360 εecondε .

Similarly, 2'-0-propyl- (a.k.a 2'-propoxy-) phoεphorothioate oligonucleotides are prepared by slight modifications of this procedure and essentially according to procedures disclosed in U.S. patent application Serial No. 08/383,666, filed February 3, 1995, which is assigned to the same assignee as the instant application and which iε incorporated by reference herein.

The 2 ' -fluoro-phosphorothioate oligonucleotideε of the invention are synthesized using 5 ' -dimethoxytrityl- 3 ' -phosphoramidites and prepared as discloεed in U.S. patent application Serial No. 08/383,666, filed February 3,

1995, and U.S. Patent 5,459,255, which issued October 8,

1996, both of which are assigned to the same assignee as the instant application and which are incorporated by reference herein. The 2 ' -fluoro-oligonucleotides are prepared using phosphoramidite chemistry and a slight modification of the standard DNA synthesis protocol (i.e., deprotection was effected using methanolic ammonia at room temperature) . PNA antisense analogs are prepared essentially as described in U.S. Patents Nos. 5,539,082 and 5,539,083, both of which (1) issued July 23, 1996, (2) are assigned to the same assignee as the instant application and (3) are incorporated by reference herein. Oligonucleotides comprising 2 , 6-diaminopurine are prepared using compounds described in U.S. Patent No. 5,506,351 which issued April 9, 1996, and which is assigned to the same assignee as the instant application and incorporated by reference herein, and materials and methods described by Gaffney et al . { Tetrahedron, 1984, 40:3),

Chollet et al . , {Nucl . Acids Res . , 1988, 16:305) and Prosnyak et al . { Genomics , 1994, 21:490). Oligonucleotides comprising 2 , 6-diaminopurine can also be prepared by enzymatic means (Bailly et al . , Proc . Natl . Acad . Sci . U. S.A . , 1996, 93 13623).

The 2 ' -methoxyethoxy oligonucleotides of the invention were synthesized essentially according to the methods of Martin et al . {Helv. Chim . Acta, 1995, 78, 486) .

For ease of synthesis, the 3' nucleotide of the 2'- methoxyethoxy oligonucleotides was a deoxynucleotide, and

2 ' -0-CH₂CH₂OCH₃.cytosines were 5-methyl cytosines, which were synthesized according to the procedures described below. B. Synthesis of 5-Methyl Cytosine Monomers:

1. 2,2 ' -Anhydro [1- (β-D-arabinofuranosyl) -5- methyluridine] : 5-Methyluridine (ribosylthymine, commercially available through Ya asa, Choshi, Japan) (72.0 g, 0.279 M) , diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to N, N- dimethylformamide (DMF, 300 mL) . The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L) , with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL) . The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid which was crushed to a light tan powder (57 g, 85% crude yield) . The material was used as is for further reactions .

2. 2 ' -0-Methoxyethyi-5-methyluridine: 2,2'-

Anhydro-5-methyluridine (195 g, 0.81 M) , tris(2- methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with methanol (200 mL) . The residue was suspended in hot acetone (1 L) . The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/methanol (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂C1₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product.

3. 2' -0-Methoxyethyi-5' -O-dimethoxytrityl-5- methyluridine: 2 ' -O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L) . A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. High presεure liquid chromatography (HPLC) εhowed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL) . The reεidue was dissolved in CHC1₃ (1.5 L) and extracted with x 500 mL of saturated NaHC0₃ and 2x 500 mL of saturated NaCl . The organic phaεe waε dried over Na₂S0₄, filtered and evaporated. 275 g of reεidue waε obtained. The reεidue waε purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional waε obtained from the impure fractions to give a total yield of 183 g (57%) .

4. 3' -O-Acetyl-2' -O-methoxyethyl-5 ' -0- dimethoxytrityl-5- ethyluridine: 2 ' -O-Methoxyethyl-5 ' -0- dimethoxytrityl-5-methyluridine (106 g, 0.167 M) ,

DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours . The reaction was monitored by thin layer chromatography (tic) by first quenching the tic sample with the addition of MeOH. Upon completion of the reaction, as judged by tic, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue waε diεεolved in CHC1₃ (800 mL) and extracted with 2x 200 mL of saturated sodium bicarbonate and 2x 200 mL of saturated NaCl . The water layers were back extracted with 200 mL of CHC1₃. The combined organicε were dried with εodium εulfate and evaporated to give 122 g of residue (approximately 90% product) . The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane (4:1) . Pure product fractions were evaporated to yield 96 g (84%) .

5. 3 ' -O-Acetyl-2¹ -O-methoxyethyl-5¹ -0- dimethoxytrityl-5-methyl-4-triazoleuridine: A first solution was prepared by disεolving 3 ' -O-acetyl-2 ' -0- methoxyethyl- 5 ' -0-dimethoxytrityl- 5 -methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L) , cooled to -5°C and stirred for 0.5 h using an overhead stirrer. P0C1₃ was added dropwise, over a 30 minute period, to the stirred εolution maintained at 0- 10°C, and the resulting mixture stirred for an additional 2 hours. The firεt solution was added dropwise, over a 45 minute period, to the later solution. The reεulting reaction mixture waε εtored overnight in a cold room. Saltε were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solidε were removed by filtration. The filtrate was washed with lx 300 mL of NaHC0₃ and 2x 300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound. 6. 2' -O-Methoxyethyl-5¹ -0-dimethoxytrityl-5- methylcytidine: A εolution of 3 ' -O-acetyl-2 ' -0- methoxyethyl-5 ' -0-dimethoxytrityl-5-methyl-4- triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄0H (30 mL) waε εtirred at room temperature for 2 hourε . The dioxane εolution waε evaporated and the residue azeotroped with MeOH (2x 200 mL) . The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainleεs steel pressure vessel. Methanol (400 mL) saturated with NH₃ gaε was added and the vessel heated to 100°C for 2 hours (thin layer chromatography, tic, showed complete conversion) . The vesεel contents were evaporated to drynesε and the reεidue waε dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL) . The organicε were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

7. N⁴-Benzoyl-2 ' -O-methoxyethyl-5 ' -0- dimethoxytrityl-5-methylcytidine: 2 ' -O-Methoxyethyl-5 ' -0- dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was disεolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) waε added with stirring. After stirring for 3 hours, tic showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL) . The residue was dissolved in CHC1₃ (700 mL) and extracted with saturated NaHC0₃ (x 300 mL) and saturated NaCl (x 300 mL) , dried over MgS0₄ and evaporated to give a residue (96 g) . The residue was chromatographed on a 1.5 kg silica column using

EtOAc/Hexane (1:1) containing 0.5% Et₃NH as the eluting solvent . The pure product fractions were evaporated to give 90 g (90%) of the title compound.

8. N⁴-Benzoyl-2' -O-methoxyethyl-5" -0- dimethoxytrityl-5-methylcytidine-3 ' -amidite: N⁴-Benzoyl-2 ' -

O-methoxyethyl-5 ' -O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was disεolved in CH₂C1₂ (1 L) . Tetrazole diiεopropylamine (7.1 g) and 2-cyanoethoxy-tetra- (isopropyl) phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmoεphere. The resulting mixture was stirred for 20 hours at room temperature (tic showed the reaction to be 95% complete) . The reaction mixture was extracted with saturated NaHC0₃ (lx 300 mL) and saturated NaCl (3x 300 mL) . The aqueouε waεheε were back- extracted with CH₂C1₂ (300 mL) , and the extractε were combined, dried over MgS0₄ and concentrated. The reεidue obtained waε chromatographed on a 1.5 kg silica column using EtOAc\Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

C. Oligonucleotide Purification: After cleavage from the controlled pore glass (CPG) column (Applied Biosyεterns) and deblocking in concentrated ammonium hydroxide, at 55°C for 18 hours, the oligonucleotides were purified by precipitation x from 0.5 M NaCl with 2.5 volumes of ethanol followed by further purification by reverεe phase high liquid pressure chromatography (HPLC) . Analytical gel electrophoresis was accompliεhed in 20% acrylamide, 8 M urea and 45 mM Triε-borate buffer (pH 7) . D. Oligonucleotide Labeling: Antiεense oligonucleotides were labeled in order to detect the presence of and/or measure the quantity thereof in sampleε taken during the course of the in vivo pharmacokinetic studies described herein. Although radiolabeling by tritium exchange iε one preferred meanε of labeling antisense oligonucleotides for such in vivo studies, a variety of other means are available for incorporating a variety of radiological, chemical or enzymatic labelε into oligonucleotideε and other nucleic acidε .

1. Tritium Exchange: Eεεentially, the procedure of Graham et al . {Nucleic Acids Research, 1993, 21:3737) was used to label oligonucleotideε by tritium exchange. Specifically, about 24 mg of oligonucleotide waε diεεolved in a mixture of 200 uL of εodium phosphate buffer (pH 7.8), 400 uL of 0.1 mM EDTA (pH 8.3) and 200 uL of deionized water. The pH of the resulting mixture was measured and adjusted to pH 7.8 using 0.095 N NaOH. The mixture was lyophilized overnight in a 1.25 mL gasketed polypropylene vial. The oligonucleotide was dissolved in 8.25 uL of b-mercaptoethanol, which acts aε a free radical scavenger (Graham et al . , Nucleic Acids Research, 1993, 21:3737), and 400 uL of tritiated H₂0 (5 Ci/gram) . The tube was capped, placed in a 90BC oil bath for 9 hours without stirring, and then briefly centrifuged to remove any condensate from the inside lid of the tube. (As an optional analytical εtep, two 10 uL aliquotε (one for HPLC analyεiε, one for PAGE analyεis) were removed from the reaction tube; each aliquot was added to a separate 1.5 mL standard microfuge tube containing 490 uL of 50 uM sodium phosphate buffer (pH 7.8).) The oligonucleotide mixture is then frozen in liquid nitrogen and transferred to a lyophilizaticn apparatus wherein lyophilization was carried out under high vacuum, typically for 3 hours . The material was then resuspended in mL of double-distilled H₂0 and allowed to exchange for 1 hour at room temperature. After incubation, the mixture was again quick frozen and lyophilized overnight. (As an optional analytical step, about 1 mg of the oligonucleotide material is removed for

HPLC analysis.) Three further lyophilizations were carried out, each with approximately 1 mL of double-distilled H₂0, to ensure the removal of any residual, unincorporated tritium. The final resuspended oligonucleotide solution iε tranεferred to a clean polypropylene vial and aεεayed. The tritium labeled oligonucleotide iε εtored at about -70BC.

2. Other Means of Labeling Nucleic Acids:

As is well known in the art, a variety of meanε are available to label oligonucleotideε and other nucleic acidε and to εeparate unincorporated label from the labeled nucleic acid. For example, double-εtranded nucleic acids can be radiolabeled by nick translation and primer extension, and a variety of nucleic acidε, including oligonucleotideε, can be terminally radiolabeled by the use of enzymes such as T4 polynucleotide kinase or terminal deoxynucleotidyl transferase (see, generally, Chapter 3 In :

Short Protocols in Molecular Biology, 2d Ed., Ausubel et al . , eds . , John Wiley & Sonε, New York, NY, pageε 3-11 to

3-38; and Chapter 10 In : Molecular Cloning : A Laboratory Manual , 2d Ed., Sambrook et al . , edε . , pages 10.1 to

10.70) . It is also well known in the art to label oligonucleotides and other nucleic acids with nonradioactive labels such as, for example, enzymes, fluorescent moieties and the like (see, for example, Beck, Methods in Enzymology, 1992, 216:143; and Ruth, Chapter 6

In -. Protocols for Oligonucleotide Conjugates (Methods in

Molecular Biology, Volume 26) Agrawal, S., ed., Humana

Press, Totowa, NJ, 1994, pages 167-185) .

Example 2 Inihilation Exposure of Oligonucleotides in Mice 1. Nebulization of oligonucleotides.

Aqueous solutions of oligonucleotides were nebulized, and the resulting aerosol was delivered to an animal model (male CD-I mice) via a nose-only inhalation system. In order to reach the bronchiolar and alveolar regions of the lung, the particle size was targeted for 1 to 5 μm. Following single or multiple exposures, mice were evaluated for signs of toxicity and designated tissues were collected for assessment of organ-specific effects and the oligonucleotide concentrations. The male CD-I mouse was chosen as the animal model for this study since considerable scientific data is available for thiε species.

2. Oliginucleotides Employed in Animal Studies

The following compounds were tested in this study:

1) ISIS 2105, a phosphorothioate antisenεe 2'- deoxyribose oligonucleotide targeted to HPV, and having the sequence :

5' -TTG-CTT-CCA-TCT-TCC-TCG-TC-3' (SEQ ID NO: 9) 2) ISIS 17009, a phosphorothioate antisense 2'- deoxyribose oligonucleotide targeted to mouse ICAM-1, having the sequence : 5' -GGA-GTC-CAG-CAC-TAG-CAC-TG-3 ' (SEQ ID NO : 10)

3) ISIS 15163, a phosphodieεter antisense 2 ' -0- methoxyethyi oligonucleotide targeted to mouse ICAM-1 (isosequence derivative of 17009) having the sequence: 5' -GGA-GTC-CAG-CAC-TAG-CAC-TG-3 ' (SEQ ID NO: 10), wherein each C is substituted by 5-methylcytosine .

Sterile sodium chloride (saline) for injection was uεed to formulate εolutions of oligonucleotide, and sodium chloride for injection was used as the control article .

3. Single Exposure of Isis 2105 in Mice

Mice were given a 30 minute nose-only exposure of solutionε of ISIS-2105 having concentrations of either 10 or 100 mg/ml, with saline controls. Calculated lung doses (see infra) were 1.2 and 12 mg/kg, respectively. Animals were necropsied at 0 minutes (at the end of exposure) , 2 hours, 8 hours, and 24 hours. Animals were generally asεessed for their health, and more limited asεeεsments were made of lung tolerability . Lung concentrationε of oligonucleotide and oligonucleotide metabolites were performed by capillary gel electrophoresis (CGE) and diεtribution of oligonucleotide within lung tisεue was determined immunohistologically.

Results:

1. General animal health

The control group and the low dose group each displayed a 7% or 13% decrease, respectively, in breathing rate during exposure. The high doεe group displayed a 28 percent decrease in breathing rate during exposure . Exposure had no effect on body weight or organ weight .

2. Histological assessment of the lung

Histological results indicated a slight induction of an inflammatory response in the low dose group, possibly attributable to increased macrophages . There was a significant inflammatory response in the high dose group, manifesting an increaεed number of macrophageε, and diεruption of alveolar εpace .

3. Elimination from the lung (See Figure 1)

Figure 1 εhowε the elimination of oligonucleotide from the lung of mice in thiε study. It can be seen that elimination appearε to be monophaεic in the low dose group, and biphasic in the high dose group. However, it may be that integrity was compromised in the high dose group; i.e., the high dose may have overdosed the lung. There was a relatively long half-life for both parent compound and metaboliteε which, in the caεe of the full length oligonucleotide, iε greater than 20 hourε and for the total oligonucleotide is greater than 40 hours. Metabolism of parent oligonucleotide in the lung appears to be faster than clearance rate from the lung, which is consistent with observations made in other organs .

4. Distribution within the lung

The oligonucleotide was distributed to all cell types in the lung, including bronchiolar and alveolar epithelium, endothelial cells, and alveolar macrophages . In addition, significant concentrationε of oligonucleotide and metaboliteε were found in lung tiεεue (by CGE analyεiε) : 80 percent of the oligonucleotide waε found to be intact at the end of the expoεure, with 50 percent remaining intact 8 hours after the exposure, and 20 to 30 percent intact 24 hours after the exposure. There were significant concentrations of oligonucleotide and metabolites found in BAL (bronchial alveolar lavage) . These are εhown in Table 1 below:

Table 1 Concentration of ISIS-2105 Found in BAL 0 hour 2 hour 8 hour 24 hour

12 mg/kg 6.3 μM 4.7 μM 1.5 μM 1.1 μM (76%) (49%) (31%) (>10%) expressed aε concentration of total oligonucleotide (% full length)

For the 12 mg/kg group, detectable levelε of oligonucleotide and/or metabolite were found in plasma: 0.6 micromolar at 0 hours (52 percent full length), and 0.3 micromolar at 2 hours (38 percent full length) . Significant concentrations were found also in the liver; 30 microgramε 24 hourε after the expoεure; 12-16 percent of intact parent compound. From theεe data it can be seen that for the high dosage group, that portion of the oligonucleotide that was delivered to plasma, is cleared relatively quickly.

The foregoing data show that high concentrations of oligonucleotide may adversely affect the breathing rate, posεibly by airway irritation, or as a result of the relatively high viscosity of the solution. Importantly, pulmonary delivery of oligonucleotide reεulted in diεtribution to all cell typeε in the lung.

Example 3

Single and Multiple Exposure Study of Oligonucleotides in Mice

1. Exposure System Design and Concepts

The exposure systemε uεed were deεigned to nebulize the test article solution or saline only. The exposure atmospheres were generated using PARI LC PLUS nebulizerε (PARI Reεpiratory Equipment, Inc, Richmond, VA) . Filtered compreεsed air was used as the air supply. Airflow rates were set and maintained at levels required to assure a consistent aerosol generation and maintain animal health. Empty ports within the generation chamber provided locations for obtaining sampleε for gravimetric and particle εize determination or analyεiε.

Atmoεphere concentration waε determined both gravimetrically (development phaεe) and by analytical meaεurementε (animal expoεure) . Glass fiber filters (Gelman #66075, Gelman scienceε, Ann Arbor, MI) were placed into in-line filter holderε. Airflow rateε were regulated to εample a known volume of teεt atmosphere. Immediately after sampling, the filters were collected and the mass concentration calculated. The filter sampleε were then proceεsed to extract and analyze the test material deposited on the filter. Analytical meaεurementε were used to calculate the inhaled dose. Samples were collected during each exposure in which animals were placed in the chambers . Particle size was measured with a Mercer style cascade impactor (Chen et al . , Fundam . Appl . Toxicol . ,

1989, 13 , 429) . The effective cut-off diameters for the impactor ranged from 4.8 microns to 0.30 microns. Particle size was measured for each oligonucleotide tested, following the first and last exposure. The Mass Median Aerodynamic Diameter (MMAD) for the three oligonucleotides ranged from 2.72 to 3.26 and the Geometric Standard Deviation (GSD) ranged from 2.44 to 2.46.

Animals were exposed in nose-only expoεure unitε εimilar to the design described by Cannon et al (1983) , Amer . Ind . Hyg. Assoc . 44 (12 ) 923-928. "Open" type restraint tubes were used to aid in the ability of the animals to thermoregulate and elimination of excetia. The pulmonary dose was calculated based on the following equation:

Pulmonary Dose =

RMV x Concentration x Time x Deposition Factor

Body Weight

Wherein:

RMV = respiratory minute volume, assumed* to be 0.03 1/min for a 30 gram mouse

Concentration = chamber concentration based on analytical methods

Time = exposure time in minutes

Deposition Factor = fraction that remains in lung, assumed* to be 10% with a particle size of 2 to 3 micrometers .

Body Weight = mean body weight in grams (30 grams was uεed as the average)

Based on this equation, and the data obtained following filter analysiε, the eεtimated pulmonary doεe for the low, mid, and high dose groupε waε approximately 0.8, 1.5 and 3.2 mg/kg, reεpectively .

2. Results:

A. Nebulization of oligonucleotides

Figure 1 showε a plot of milligrams oligonucleotide collected in impinger versuε time. These data show the successful nebulization of oligonucleotide; i.e., that the oligonuclotide is uniformly nebulized, and that the size of the resultant particles is not altered over time.

B. Toxicity

Data collected for assessment of potential toxicity included clinical observations, body weight, clinical pathology (hematology and serum chemistry) , gross necropsy (observations and organ weights) and microscopic examination of selected tissues. There were no clinical observationε attributable to oligonucleotide adminiεtration. Body weight gain and clinical pathology parameterε were all within the normal range for male CD-I mice. All mice survived to their respective necropsy interval (following either a single or four exposures) and there were no gross observations at necropsy or changes in organ weights .

Microscopic observationε were limited to the lungs of 5 of 5 mice in the 4 exposure-high dose ISIS 2105 group, 2 of 5 mice in the 4 exposure-mid dose ISIS 2105 group, and 1 of 4 or 1 of 5 mice in the high dose ISIS 15163 single or multiple exposure groups, respectively. These effects in the lungs were described as a multifocal inflammatory cell infiltrate that was regarded as being minimal in severity. Similar observationε have been noted following intravenous administration of oligonucleotides in mice and these effects have been attributed to immune stimulation aspects that occurs in rodents administered this class of compoundε.

No other changes were noted in the lungs, and there were no observations of effects noted for the other tissues examined (liver, kidney, spleen, and nasal passages) .

C. Organ Distribution

The concentration of each oligonucleotide and its metabolites waε determined in tiεsue samples of lung, liver, kidney and spleen. Table 1 and Table 2 εhow the concentrationε of total oligonucleotide (parent oligonucleotide and oligonucleotide metabolites) in the lung, liver and kidney. Concentrations observed in the lung were dose-dependent and were greater in mice administered four exposures versus a single exposure. Similar concentrations were observed in lungs of mice exposed to the phosphorothioate oligonucleotides, ISIS 2105 and ISIS 17709, while higher concentrations were observed in mice exposed to ISIS 15163, a phosphodiester 2'- methoxyethyl modified oligonucleotide. Minimal concentrations of total oligonucleotide were observed in the liver or kidney of mice exposed to ISIS 2105 or ISIS 17009 and the liver of mice expoεed to ISIS 15163. Slightly greater concentrationε were obεerved in the kidney of mice exposed to ISIS 15163, these concentrations were dose- and exposure number-dependent. TABLE 2

Concentration of Total Oligonucleotide Following A Single

Nose-Only Inhalation Exposure in CD-I Mice

Tissue Type

Oligonucleotide Lung Liver Kidney

ISIS 2105

Low 27.4 + 7.5 NQ NQ

Middle 61.7 + 9.9 NQ NQ

High 62.4 + 15.3 NQ 4.0 + 3.6

ISIS 17009

Low 22.9 ± 10.8 0.4 + 0.2 NQ

Middle 48.6 + 15.1 1.4 + 2.6 NQ

High 71.8 + 39.2 2.5 + 2.5 2.5 + 2.5

ISIS 15163

Low 26.9 + 22.2 NQ 2.0 + 1.3

Middle 91.1 + 53.7 NQ 10.2 + 3.5

High 255.9 + 104.3 NQ 30.1 + 13.7

TABLE 3

Concentration of Total Oligonucleotide Following Multiple

(Four) Nose-Only Inhalation Exposures in CD-I Mice

Tissue Type

Oligonucleotide Lung Liver Kidney

ISIS 2105

Low 48.8 + 20.8 NQ NQ

Middle 105.0 + 26.3 0.2 + 0.3 0.3 + 0.4

High 103.9 + 31.3 1.1 + 1.6 NQ

ISIS 17009

Low 61.2 + 16.1 NQ NQ

Middle 75.7 + 10.8 4.7 + 5.5 NQ

High 87.9 + 33.4 0.7 + 1.4 NQ

ISIS 15163

Low NQ NQ 5.3 + 3.3

Middle 110.1 + 43.7 NQ 61.0 + 64.5

High 319.5 + 84.0 NQ 57.2 + 17.2

Note: NQ = in all animals, or in all animals but one, no oligonucleotide was found at limit of detection.

As can be seen, nose-only inhalation exposure of oligonucleotide waε well tolerated in mice. Effectε in the lung were limited to a minimal cellular infiltrate that was likely due to the general immune stimulation that occurs in mice administered thiε class of compounds. Lung was also the tissue with the greatest concentration of

Claims

oligonucleotide. Minimal oligonucleotide concentrations were obεerved in the other organε evaluated, and no histologic alterations were observed in these organs. Similar observationε were noted for the phosphorothioate oligonucleotides, i.e. tissue concentrations and tissue effects . The 2 ' -methoxyethyi modified phosphodieεter oligonucleotide (ISIS 15163) waε detected in greater concentrations in lung, but histologic alterations were limited to 1 animals in each of the single and multiple exposure groups.It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety. Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modificationε may be made without departing from the εpirit of the invention. It iε therefore intended that the appended claimε cover all such equivalent variations as fall within the true spirit and scope of the invention. WHAT IS CLAIMED IS:

1. A pharmaceutical composition for pulmonary delivery of an oligonucleotide comprising at least one oligonucleotide wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' - deoxyribofuranoεyl sugar moiety or at least one internucleotide linkage within said oligonucleotide is not a phosphodiester or a phosphorothioate linkage.

2. The pharmaceutical composition of claim 1, wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' -deoxyribofuranosyl sugar moiety.

3. The pharmaceutical composition of claim 2 wherein said nucleoside unit is a 2 ' -O-substituted nucleoside unit.

4. The pharmaceutical composition of claim 3 wherein said 2-O-substituent of said 2 ' -O-substituted nucleoside unit is a 2 ' -O-alkoxyalkoxy substituent.

5. The pharmaceutical composition of claim 3 wherein said 2-O-substituent of εaid 2 ' -O-substituted nucleoside unit is a 2 ' -O-dialkylaminooxyalkyl substituent.

6. The pharmaceutical composition of claim 1, wherein at least one internucleotide linkage within said oligonucleotide is not a phosphodieεter or a phosphorothioate linkage.

7. The pharmaceutical composition of claim 6 wherein at least one internucleotide linkage within said oligonucleotide is a 3 ' -methylenephosphonate, a non- phoεphoruε containing oligonucleoside linkage, a 2' -5' linkage or is a 3 ' -deoxy-3 ' -amino phosphoramide linkage.

8. The pharmaceutical composition of claim 1 further compriεing one or more pharmaceutically acceptable carrier .

9. The pharmaceutical compoεition of claim 1 wherein εaid compoεition iε in aqueous media.

10. The pharmaceutical composition of claim 9 wherein said aqueous media is sterilized, pyrogen free water.

11. The pharmaceutical compoεition of claim 9 wherein εaid aqueous media is saline solution.

12. The pharmaceutical composition of claim 1 wherein said compoεition is a powder.

13. The pharmaceutical composition of claim 1, wherein said oligonucleotide is an antiεenεe oligonucleotide.

14. The pharmaceutical compoεition of claim 13 wherein εaid antiεenεe compound modulateε the expression of a protein or modulates a rate of cellular proliferation.

15. The pharmaceutical composition of claim 14 wherein εaid antiεenεe oligonucleotide modulateε expreεεion of a cellular adhesion protein.

16. The pharmaceutical composition of claim 13, wherein the antiεenεe oligonucleotide iε antiεenεe to a genetic εequence implicated in a disease or disorder.

17. The pharmaceutical composition of claim 13, wherein said diseaεe or diεorder iε asthma, a cancer of the lung, pulmonary fibrosis, rhinovirus, tuberculosis, bronchitis, or pneumonia.

18. The pharmaceutical composition of claim 13, wherein said antisenεe oligonucleotide iε antiεense to a portion of a gene coding for a cytokine .

19. The pharmaceutical composition of claim 13 wherein said antisense oligonucleotide is antisense to a portion of a gene coding for ICAM-1, ELAM-1, VCAM-1, B7-1, B7-2, CD40, LFA-3, PECAM-1, a ras oncogene, an H-ras oncogene, a K-ras oncogene, or Protein Kinase C.

20. The pharmaceutical composition of claim 13 wherein said antisense oligonucleotide is antisense to a unique portion of the genome of MycoJbacterium tuberculosis,

M. bovis , or Streptococcus pneumoniae .

21. The pharmaceutical composition of claim 13 wherein said antisense oligonucleotide is antisense to a portion of a gene coding for ICAM-1.

22. The pharmaceutical composition of claim 13 wherein said antiεenεe oligonucleotide iε antiεenεe to a portion of a gene coding for ELAM-1.

23. The pharmaceutical compoεition of claim 13 wherein εaid antiεense oligonucleotide is antisenεe to a portion of a gene coding for VCAM-1.

24. The pharmaceutical compoεition of claim 13 wherein said antisense oligonucleotide is antisenεe to a portion of a gene coding for B7-1.

25. The pharmaceutical composition of claim 13 wherein said antisense oligonucleotide is antisense to a portion of a gene coding for B7-2.

26. The pharmaceutical composition of claim 13 wherein said antisense oligonucleotide is antisense to a portion of a gene coding for CD40.

27. The pharmaceutical compoεition of claim 1 wherein εaid antiεense oligonucleotide is antisense to a portion of a gene coding for LFA-3.

28. The pharmaceutical composition of claim 13 wherein said antisenεe oligonucleotide iε antiεenεe to a portion of a gene coding for PECAM-1.

29. The pharmaceutical compoεition of claim 13 wherein εaid antiεenεe oligonucleotide iε antisense to a portion of a gene coding for a ras oncogene.

30. The pharmaceutical composition of claim 13 wherein said antisense oligonucleotide is antiεenεe to a portion of a gene coding for H-raε oncogene.

31. The pharmaceutical composition of claim 13 wherein said antisenεe oligonucleotide iε antiεenεe to a portion of a gene coding for K-raε oncogene.

32. The pharmaceutical compoεition of claim 13, wherein said antiεense oligonucleotide is antiεense to a portion of a gene coding for Protein Kinase C.

33. The pharmaceutical composition of claim 13 compriεing more than one antiεenεe oligonucleotide.

34. The pharmaceutical compoεition of claim 1 wherein εaid oligonucleotide is a ribozyme, an external guide sequence, or an antisense peptide nucleic acid.

35. The pharmaceutical composition of claim 1 wherein said oligonucleotide is an aptamer or a molecular decoy .

36. The pharmaceutical composition of claim 9 wherein said aqueouε media iε εterilized, pyrogen free buffer εolution.

37. A method for the adminiεtration of an nucleic acid therapeutic or diagnostic composition comprising: preparing a nucleic acid therapeutic or diagnostic composition; aerosolizing the nucleic acid composition; introducing the aerosolized nucleic acid composition into the lung of a mammal; and wherein the aerosolized nucleic acid compoεition comprises at least one oligonucleotide wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' -deoxyribofuranosyl sugar moiety or at least one internucleotide linkage within said oligonucleotide is not a phosphodiester or a phosphorothioate linkage.

38. The method of claim 37, wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' -deoxyribofuranosyl sugar moiety.

39. The method 38 wherein said nucleoside unit is a 2 ' -O-substituted nucleoside unit.

40. The method of claim 39 wherein said 2-0- substituent of said 2 ' -O-substituted nucleoside unit is a

2 ' -O-alkoxyalkoxy substituent .

41. The method of claim 39 wherein said 2-O- substituent cf said 2 ' -O-subεtituted nucleoside unit is a 2 ' -O-dialkylaminooxyalkyl subεtituent .

42. The method of claim 37, wherein at least one internucleotide linkage within said oligonucleotide is not a phosphodiester or a phosphorothioate linkage.

43. The method of claim 42 wherein at leaεt one internucleotide linkage within εaid oligonucleotide iε a

3 ' -methylenephosphonate, a non-phosphoruε containing oligonucleoside linkage, a 2 '-5' linkage or is a 3 ' -deoxy- 3 ' -amino phosphoramide linkage.

44. The method of claim 37 wherein said pharmaceutical composition further compriεeε one or more pharmaceutically acceptable carriers.

45. The method of claim 37 wherein εaid nucleic acid therapeutic or diagnoεtic compoεition is in aqueouε media .

46. The method of claim 37 wherein εaid nucleic acid therapeutic or diagnoεtic compoεition is sterilized, pyrogen free water.

47. The method of claim 37 wherein said nucleic acid therapeutic or diagnostic compoεition is saline solution.

48. The method of claim 37 wherein said nucleic acid therapeutic or diagnostic compoεition is a powder.

49. The method of claim 37 wherein the nucleic acid therapeutic composition contains more than one oligonucleotide .

50. The method of claim 37 wherein the oligonucleotide iε an antiεenεe oligonucleotide.

51. The method of claim 37 wherein the nucleic acid therapeutic compoεition is aerosolized solution consists essentially of an antisense oligonucleotide in saline εolution.

52. A method of treating an animal having or suεpected of having a disease or disorder that is treatable with one or more nucleic acids comprising administering a therapeutically effective amount of an aerosolized nucleic acid composition to the lung of the animal, wherein the aerosolized nucleic acid composition compriseε at least one oligonucleotide wherein the sugar moiety of at least one nucleoside unit of said oligonucleotide is not a 2 ' - deoxyribofuranosyl sugar moiety or at leaεt one internucleotide linkage within εaid oligonucleotide is not a phosphodieεter or a phoεphorothioate linkage.

53. A method of inveεtigating the role of gene or gene product in an animal other than a human compriεing adminiεtering a therapeutically effective amount of an aeroεolized nucleic acid compoεition to the lung of the animal, wherein the aeroεolized nucleic acid compoεition compriεeε at leaεt one oligonucleotide wherein the εugar moiety of at leaεt one nucleoεide unit of said oligonucleotide iε not a 2 ' -deoxyribofuranoεyl εugar moiety or at leaεt one internucleotide linkage within εaid oligonucleotide iε not a phoεphodieεter or a phosphorothioate linkage.

54. A method for delivering an oligonucleotide therapeutic or diagnostic compound to the lung of an animal compriεing applying to said lung a pharmaceutical composition according to claim 1.

55. The method of claim 54 wherein said oligonucleotide is delivered within cells of said lung.

56. The method of claim 55 wherein said animal is known or suspected to suffer from a diseaεe or diεorder.

57. The method of claim 56 wherein εaid diεeaεe or disorder is asthma, a cancer of the lung, pulmonary fibrosis, rhinovirus, tuberculosis, bronchitis, or pneumonia.

58. The method of claim 37 wherein the nucleic acid therapeutic composition is aerosolized solution consists essentially of an antisense oligonucleotide in buffer solution.

59. A method of modulating the expreεsion of a gene in an animal comprising administering to said animal the pharmaceutical composition of claim 1.

60. A method of modulating the expresεion of a gene in an animal comprising administering to said animal the pharmaceutical composition of claim 1.

61. A medical device for pulmonary delivery of an aerosol comprising a pharmaceutical composition in accordance ith claim 1.

62. A pharmaceutical composition according to claim 1, wherein said oligonucleotide is selected from the group consiεting of ISIS-15839, ISIS-13312, ISIS-9605, ISIS-9606, ISIS-14859, ISIS-17709, ISIS-17044, ISIS-28089 and ISIS-104838.

63. A method according to claim 37, wherein said oligonucleotide is selected from the group consisting of

ISIS-15839, ISIS-13312, ISIS-9605, ISIS-9606, ISIS-14859, ISIS-17709, ISIS-17044, ISIS-28089 and ISIS-104838.